register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT06907485 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY22120058"
]
},
{
"id_field": "secondary_id",
"id_value": [
"STUDY22120058"
]
}
] | https://clinicaltrials.gov/study/NCT06907485 | A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients | This clinical trial focuses on pediatric patients aged 2 up to 18 years of age with a new or recurrent pediatric brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal. 5-aminolevulinic acid (5-ALA) is FDA-approved for improving brain tumor visualization in adults durin... | A Multicenter Study to Assess the Feasibility of Gleolan (ALA / Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration | [
{
"description": "Pediatric patients diagnosed with a new or recurrent brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal will receive aminolevulinic acid hydrochloride prior to surgery for resection of the brain tumor.",
"name": "Aminolevulinic acid hyd... | [
{
"design_group_description": "Single arm study administering a single oral solution of aminolevulinic acid hydrochloride at a dose of 20 mg/kg body weight, 6-12 hours prior to brain surgery for resection of the tumor.",
"design_group_title": "Aminolevulinic acid hydrochloride",
"design_group_type": "Ex... | [
"Pediatric Brain Tumor"
] | [
"University of Pittsburgh"
] | [
"NX Development Corp.",
"University of Pittsburgh Medical Center",
"Brain Research Foundation",
"Advocate Health Care Network"
] | [
[
{
"name": "盐酸氨酮戊酸",
"lang": "CN"
},
{
"name": "Aminolevulinic Acid Hydrochloride",
"lang": "EN"
},
{
"name": "アミノレブリン酸塩酸塩",
"lang": "JP"
}
]
] | null |
NCT01817582 | [
{
"id_field": "org_study_id",
"id_value": [
"813"
]
}
] | https://clinicaltrials.gov/study/NCT01817582 | Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) | This study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (Lotemax®) gel 0.5 percent (%) administered twice daily (BID) with or without cyclosporine ophthalmic emulsion (Restasis) 0.05% administered BID, and Restasis 0.05% treatment alone for 12... | A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax® Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED) | [
{
"description": "Lotemax gel will be administered as per the dose and schedule specified in the arms.",
"name": "Lotemax",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"loteprednol etabonate ophthalmic gel 0.5%"
],
"type": "Drug"
},
{
"description": "... | [
{
"design_group_description": "Participants will administer lotemax gel 0.5 % BID in both eyes (OU) for 2 weeks, then administer both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administer restasis emulsion 0.05% BID OU for 8 weeks. Participants will also receive preservative-free Soot... | [
"Keratoconjunctivitis Sicca"
] | [
"Bausch & Lomb, Inc."
] | [
"Synteract, Inc."
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "氯替泼诺",
"lang": "CN"
},
{
"name": "Loteprednol Etabonate",
"lang": "EN"
}
]
] | null |
NCT06933706 | [
{
"id_field": "org_study_id",
"id_value": [
"2025P000672"
]
},
{
"id_field": "acronym",
"id_value": [
"LION"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2025P000672"
]
}
] | https://clinicaltrials.gov/study/NCT06933706 | Losartan to Improve Outcomes After Multi-ligament Knee Injury | Multi-ligament knee injuries (MLKIs) can occur during military training, sports injuries, or traumatic events such as motor vehicle accidents and can be devastating events. These complex injuries involving disruption of 2 or more ligaments often coincide with injuries to arteries, nerves, tendons, menisci, and/or fract... | Losartan to Improve Outcomes After Multi-ligament Knee Injury | [
{
"description": "Losartan is an angiotensin-II inhibitor that modulates the renin-angiotensin system by blocking the activation of angiotensin type 1 receptors, thus preventing binding with angiotensin-II and decreasing blood pressure. Losartan has a broader therapeutic potential for muscle healing and treatme... | [
{
"design_group_description": "Participants randomized to the Losartan arm will be asked to take 25 mg of losartan per day for 30 days.",
"design_group_title": "Losartan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": ... | [
"Multi-ligament Knee Injury"
] | [
"The Brigham & Women's Hospital, Inc."
] | [
"University of Kentucky",
"Walter Reed National Military Medical Center"
] | [
[
{
"name": "氯沙坦钾",
"lang": "CN"
},
{
"name": "Losartan Potassium",
"lang": "EN"
},
{
"name": "ロサルタンカリウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LION"
}
] |
NCT07216690 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00526530"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21DA063854"
]
}
] | https://clinicaltrials.gov/study/NCT07216690 | Pregnenolone as a Treatment for Cannabis Intoxication | The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research ... | Pregnenolone as a Treatment for Cannabis Intoxication | [
{
"description": "Cannabis brownie, 25mg THC",
"name": "Cannabis",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"THC",
"delta-9-THC",
"delta-9-tetrahydrocannabinol"
],
"type": "Drug"
},
{
"description": "Pregnenolone, low dose, one 250mg pr... | [
{
"design_group_description": "Placebo brownie, 0mg THC; two 0 mg pregnenolone capsules",
"design_group_title": "Placebo Brownie and Capsules",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"int... | [
"Cannabis Intoxication"
] | [
"The Johns Hopkins University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "屈大麻酚",
"lang": "CN"
},
{
"name": "Dronabinol",
"lang": "EN"
}
],
[
{
"name": "孕烯醇酮",
"lang": "CN"
},
{
"name": "Pregnenolone",
"lang": "EN"
}
]
] | null |
NCT02314156 | [
{
"id_field": "org_study_id",
"id_value": [
"NCI 2013-01-03"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2014-02412"
]
},
{
"id_field": "secondary_id",
"id_... | https://clinicaltrials.gov/study/NCT02314156 | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | This randomized trial studies transdermal or oral telapristone acetate in treating patients undergoing surgery to remove the breast (mastectomy). Telapristone acetate may help prevent breast cancer from forming in premenopausal women. Giving telapristone acetate transdermally may be safer and have fewer side effects th... | Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy | [
{
"description": "Given transdermally",
"name": "Telapristone Acetate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CDB-4124",
"Proellex",
"Progenta"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "Placebo",
"normalized... | [
{
"design_group_description": "Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.",
"design_group_title": "Arm I (transdermal telapristone acetate)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"inter... | [
"BRCA1 Mutation Carrier",
"BRCA2 Mutation Carrier",
"Ductal Breast Carcinoma In Situ",
"Lobular Breast Carcinoma In Situ",
"Stage 0 Breast Cancer",
"Stage IA Breast Cancer",
"Stage IB Breast Cancer",
"Stage IIA Breast Cancer",
"Stage IIB Breast Cancer"
] | [
"Northwestern University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "醋酸特拉司酮",
"lang": "CN"
},
{
"name": "Telapristone Acetate",
"lang": "EN"
}
]
] | null |
NCT01382706 | [
{
"id_field": "org_study_id",
"id_value": [
"4B-10-4"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-01108"
]
}
] | https://clinicaltrials.gov/study/NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by kil... | Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment | [
{
"description": "Given IV",
"name": "docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"RP 56976",
"TXT",
"Taxotere"
],
"type": "Drug"
},
{
"description": "Given PO",
"name": "lapatinib ditosylate",
"normalized_type": "3d1aa... | [
{
"design_group_description": "Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type... | [
"Recurrent Bladder Cancer",
"Stage III Bladder Cancer",
"Stage IV Bladder Cancer",
"Transitional Cell Carcinoma of the Bladder"
] | [
"University of Southern California"
] | [
"National Cancer Institute",
"GSK Plc"
] | [
[
{
"name": "二甲苯磺酸拉帕替尼",
"lang": "CN"
},
{
"name": "Lapatinib Ditosylate Hydrate",
"lang": "EN"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
{
"name": "ドセタキセル",
"lang": "JP"
}
... | null |
NCT03380728 | [
{
"id_field": "org_study_id",
"id_value": [
"72938717.3.0000.5440"
]
}
] | https://clinicaltrials.gov/study/NCT03380728 | Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | Approximately 5% of the world's adult population has some alcohol-related disorder, which in addition is associated with 3% of all deaths in the world. In Brazil, harmful use and dependence on alcohol reach about 10% of the population, with alcohol being one of the main factors of disease and mortality. Although the me... | Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | [
{
"description": "The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.",
"name": "Ibogaine Hydrochloride",
... | [
{
"design_group_description": "Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7",
"design_group_title": "Ibogaine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interventio... | [
"Alcoholism"
] | [
"University of Sao Paulo"
] | [
"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior",
"Conselho Nacional de Desenvolvimento Cientifico e Tecnológico"
] | [
[
{
"name": "伊博格碱",
"lang": "CN"
},
{
"name": "Ibogaine",
"lang": "EN"
}
]
] | null |
NCT02784444 | [
{
"id_field": "org_study_id",
"id_value": [
"MSDC-0602K-C009NASH"
]
},
{
"id_field": "acronym",
"id_value": [
"EMMINENCE"
]
}
] | https://clinicaltrials.gov/study/NCT02784444 | A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH | This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis. | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™) | [
{
"description": "MSDC-0602K capsules",
"name": "MSDC-0602K",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo capsules",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "MSDC-0602K Dose 1 capsule taken once daily for 360 days",
"design_group_title": "MSDC-0602K Dose 1 capsules",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"interve... | [
"Non-alcoholic Fatty Liver Disease",
"Non-alcoholic Steatohepatitis",
"NASH - Nonalcoholic Steatohepatitis"
] | [
"Cirius Therapeutics, Inc."
] | [
"Chiltern International, Inc."
] | [
[
{
"name": "MSDC-0602K",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "542ad228de550e5a238e923d22254830",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8ae4a2ad39a2ea8e28a88a0059505885",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "EMM... |
NCT06204237 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-505287-11-01"
]
},
{
"id_domain": "UMCG PaNaMa registry",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"17489"
]
},
{
"id_field": "acronym",
"id_value": [
"CHASE"
]
... | https://clinicaltrials.gov/study/NCT06204237 | Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) | The goal of this Phase 0 clinical trial is to evaluate safety and biodistribution of [89Zr]Zr-DFO-APAC in patients with peripheral arterial occlusive disease / critical limb ischemia (PAOD/CLI) and healthy volunteers. The main questions it aims to answer are:<br/>* What is the safety, tolerability and pharmacokinetic p... | Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC (Phase 0) in Subjects With Peripheral Arterial Occlusive Disease / Critical Limb Ischemia (PAOD/CLI) and Healthy Volunteers - an Open Label PET Study (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron... | [
{
"description": "All participants will receive a single i.v. injection of [89Zr]Zr-DFO-APAC 15 MBq (Megabecquerel).",
"name": "[89Zr]Zr-DFO-APAC",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "The IMP administration will be followed by whole-body... | [
{
"design_group_title": "[89Zr]Zr-DFO-APAC",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "The IMP administration will be followed by whole-body PET/CT scanning (day 1), and r... | [
"Peripheral Arterial Occlusive Disease",
"Critical Limb Ischemia"
] | [
"Aplagon Oy"
] | [
"Tracer Europe BV"
] | [
[
{
"name": "[89Zr]Zr-DFO-APAC",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CHASE"
}
] |
NCT07176923 | [
{
"id_field": "org_study_id",
"id_value": [
"CS-121-01"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CS-121-01"
]
}
] | https://clinicaltrials.gov/study/NCT07176923 | CS-121 APOC3 Base Editing in FCS | This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia ... | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3, in Adults With Familial Chylomicronemia Syndrome | [
{
"description": "CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. In this study, participants receive a single intravenous infusion of CS-121 at escalating dose levels. The investigational product is designed to reduce ApoC3 prote... | [
{
"design_group_description": "Participants in this arm will receive a single low dose of CS-121.",
"design_group_title": "Single Low Dose CS-121",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"inter... | [
"Familial Chylomicronemia Syndrome (FCS)"
] | [
"CorrectSequence Therapeutics Co., Ltd."
] | [
"Anhui Medical University No. 1 Affiliated Hospital"
] | [
[
{
"name": "CS-121",
"lang": "EN"
}
]
] | null |
NCT07290205 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY25110017"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R35GM146822"
]
},
{
"id_field": "acronym",
"id_value": [
"REMAZ"
]
}
] | https://clinicaltrials.gov/study/NCT07290205 | Remimazolam NeuroImaging | This is a single-arm functional MRI study that will determine the effects of remimazolam on cognition and brain activity and connectivity at rest, during noxious stimulation, and during a memory encoding task | Neuroimaging of Sedation With Remimazolam | [
{
"description": "Subjects in this group will receive an intravenous infusion of this drug, during a portion of the study.",
"name": "Remimazolam",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Experimental acute pain stimulus will be delivered us... | [
{
"design_group_description": "Single-arm study. All subjects receive remimazolam and painful electric nerve stimulation, while being imaged with MRI, as described in the interventions.",
"design_group_title": "Remimazolam+Pain",
"design_group_type": "Experimental",
"design_group_type_normalized_id"... | [
"Anesthesia",
"Pain",
"Remimazolam"
] | [
"University of Pittsburgh"
] | [
"National Institute of General Medical Sciences"
] | [
[
{
"name": "甲苯磺酸瑞马唑仑",
"lang": "CN"
},
{
"name": "Remimazolam Tosylate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "REMAZ"
}
] |
NCT03336372 | [
{
"id_field": "org_study_id",
"id_value": [
"IIS-Picato-1386"
]
}
] | https://clinicaltrials.gov/study/NCT03336372 | Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients | Patients at least 18 years of age will be enrolled in the study to assess the efficacy and tolerability of Picato gel in the treatment of molluscum contagiosum. Patients must have an immunocompromised condition due to taking immunosuppressive drugs or having an inherited disease affecting the immune system. | Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients | [
{
"description": "Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights",
"name": "Picato",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Picato topical gel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights",
... | [
"Molluscum Contagiosum"
] | [
"Center For Clinical Studies Ltd. LLP"
] | [
"Leo Pharma, Inc."
] | [
[
{
"name": "巨大戟醇甲基丁烯酸酯",
"lang": "CN"
},
{
"name": "Ingenol Mebutate",
"lang": "EN"
}
]
] | null |
NCT06216938 | [
{
"id_field": "org_study_id",
"id_value": [
"HCC 22-138"
]
}
] | https://clinicaltrials.gov/study/NCT06216938 | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates ... | Phase I Pilot Study of RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | [
{
"description": "Vusolimogene Oderparepvec is a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities.",
"name": "Vusolimogene oderparepvec (RP1)",
"normalized_type": "30faef638ae74cc7957c665e1b5... | [
{
"design_group_description": "Patients will receive 3 doses of RP1 (1.0 mL/injection; 10e6 PFU/mL for the first dose, and 10e7 mL for the subsequent 2 doses). The drug will be injected into the skin at the tumor biopsy site at baseline (day 1), day 15, and day 21, 4-5 weeks prior to SOC WLE and SLNB. Definitiv... | [
"Melanoma"
] | [
"University of Pittsburgh"
] | [
"Replimune, Inc."
] | [
[
{
"name": "Vusolimogene oderparepvec",
"lang": "EN"
}
]
] | null |
NCT05851378 | [
{
"id_field": "org_study_id",
"id_value": [
"22925"
]
},
{
"id_domain": "NCI Clinical Trials Reporting Program (CTRP)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2023-03744"
]
},
{
"id_field": "secondary_id",
"id_type... | https://clinicaltrials.gov/study/NCT05851378 | Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma | This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma. | Hyperpolarized Carbon-13 Alpha-ketoglutarate Metabolic Imaging in IDH Mutant Glioma | [
{
"description": "Given intravenously at time of imaging",
"name": "Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Hyperpolarized C13-aKG",
"HP C13-aKG"
],
"type": "Drug"
},
{
"descriptio... | [
{
"design_group_description": "Cohort 1 will be comprised of 10 participants with Isocitrate dehydrogenase (IDH) mutant glioma who may or may not have received prior treatment for optimizing imaging protocol. Participants will be injected with 0.67ml/kg actual body weight of 100 millimolar (mM) of α-KG solution... | [
"Adult Gliomas, Mixed"
] | [
"The University of California, San Francisco"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Hyperpolarized Carbon 13 Alpha-ketoglutarate",
"lang": "EN"
}
]
] | null |
NCT04630444 | [
{
"id_field": "org_study_id",
"id_value": [
"2016P002687"
]
}
] | https://clinicaltrials.gov/study/NCT04630444 | Riluzole Effects on Hippocampus Biomarkers | To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS. | An Investigational Study of Riluzole Effects on Hippocampus Biomarkers | [
{
"description": "30 PTSD patients with riluzole 100 mg daily (50 mg bid).",
"name": "Riluzole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "30 PTSD patients receiving riluzole 100 mg daily (50 mg bid).",
"design_group_title": "Intervention Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_d... | [
"Posttraumatic Stress Disorder"
] | [
"McLean Hospital, Inc."
] | [
"Brain & Behavior Research Foundation"
] | [
[
{
"name": "利鲁唑",
"lang": "CN"
},
{
"name": "Riluzole",
"lang": "EN"
},
{
"name": "リルゾール",
"lang": "JP"
}
]
] | null |
NCT06692933 | [
{
"id_field": "org_study_id",
"id_value": [
"20533"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U54AT008909"
]
}
] | https://clinicaltrials.gov/study/NCT06692933 | Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel | The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use... | Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel | [
{
"description": "Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel",
"name": "Cannabidiol in the form of hemp",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CBD"
],
"type": "Drug"
},
{
"description": "75 mg oral clopidogrel",... | [
{
"design_group_description": "Participants will be administered a single oral dose (75 mg) of clopidogrel. Blood and urine will be collected for 24 hours.",
"design_group_title": "Arm 1: clopidogrel alone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f... | [
"Interaction"
] | [
"Washington State University"
] | [
"National Center For Complementary & Integrative Health",
"Office of Dietary Supplements"
] | [
[
{
"name": "硫酸氢氯吡格雷",
"lang": "CN"
},
{
"name": "Clopidogrel Bisulfate",
"lang": "EN"
},
{
"name": "クロピドグレル硫酸塩",
"lang": "JP"
}
],
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
]
... | null |
NCT04369560 | [
{
"id_field": "org_study_id",
"id_value": [
"HCC 20-054"
]
}
] | https://clinicaltrials.gov/study/NCT04369560 | Virtual Histology of the Bladder Wall for Bladder Cancer Staging | This is a phase Ib study of the safety and performance of a novel intravesical contrast-enhanced Magnetic Resonance Imaging protocol for determination of bladder cancer stage prior to transurethral resection of bladder tumor (21 subjects) or prior to radical cystectomy for muscle invasive disease (21 subjects). Subject... | Virtual Histology of the Bladder Wall for Bladder Cancer Staging; A Novel Intravesical Contrast-Enhanced MRI for Bladder Cancer Staging | [
{
"description": "60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.",
"name": "Magnetic Resonance Imaging",
"normalized_type": "aea6c8ca7e224555aa65fa8f8524d3ca",
"type": "Diagnostic Test"
},
{
"description": "A par... | [
{
"design_group_description": "Prior to planned surgical resection, subjects will undergo a single Magnetic Resonance Imaging study: a single breath-hold pre-contrast image followed by sterile placement of a temporary urethral catheter for instillation of a 50mL solution containing Gadobutrol (4 mM) plus ferumo... | [
"Urinary Bladder Neoplasms"
] | [
"University of Pittsburgh"
] | [
"National Cancer Institute"
] | [
[
{
"name": "非莫妥尔",
"lang": "CN"
},
{
"name": "Ferumoxytol",
"lang": "EN"
}
],
[
{
"name": "钆布醇",
"lang": "CN"
},
{
"name": "Gadobutrol",
"lang": "EN"
},
{
"name": "ガドブトロール",
"lang": "JP"
}
]
] | null |
NCT07067905 | [
{
"id_field": "org_study_id",
"id_value": [
"S2025-149-02"
]
}
] | https://clinicaltrials.gov/study/NCT07067905 | Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma | A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also ... | Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma | [
{
"description": "68Ga-XT771 is injected intravenously with a dose of 4-8 mCi",
"name": "68Ga-XT771",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Experimental: 68Ga-XT771 Subjects with suspected or confirmed clear cell renal cell carcinoma will receive an intravenous injection of 68Ga-XT771followed by PET imaging. The subjects will also receive a 18F-FDG PET/CT or 68Ga-DPI-4552 scan within a four-week period.<br/>Pathologic... | [
"Clear Cell Renal Cell Carcinoma and Glioblastoma"
] | [
"Chinese People's Liberation Army General Hospital"
] | [
"Sinotau Pharmaceutical Group"
] | [
[
{
"name": "68Ga/64Cu-FAPI-XT117",
"lang": "EN"
}
]
] | null |
NCT04218409 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB201902618-N"
]
},
{
"id_domain": "UF OnCore",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"OCR30384"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"... | https://clinicaltrials.gov/study/NCT04218409 | Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pa... | Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | [
{
"description": "Oral oxycodone 5 mg orally",
"name": "OxyCODONE 5 mg Oral Tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intranasal oxytocin administration (48 IU)",
"name": "Oxytocin nasal spray",
"normalized_type": "3d1aa88261d... | [
{
"design_group_description": "Combined effects of oxycodone and oxytocin",
"design_group_title": "oxycodone (5mg) + intranasal oxytocin (48 IU)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"i... | [
"Pain"
] | [
"University of Florida"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸羟考酮",
"lang": "CN"
},
{
"name": "Oxycodone Hydrochloride",
"lang": "EN"
},
{
"name": "オキシコドン塩酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "缩宫素",
"lang": "CN"
},
{
"name": "Oxytocin",
"lang": "EN"
},
{... | null |
NCT00825591 | [
{
"id_field": "org_study_id",
"id_value": [
"0804003699"
]
},
{
"id_field": "secondary_id",
"id_value": [
"TRSH-SAR"
]
}
] | https://clinicaltrials.gov/study/NCT00825591 | Biological Clock Dysfunction in Optic Nerve Hypoplasia | Background: Optic Nerve Hypoplasia (ONH) is a leading cause of blindness in children. For unclear reasons, the incidence of ONH is increasing, with ONH affecting about 1 in 10,000 live-born infants. In addition to visual deficits, ONH is associated with varying degrees of hypopituitarism, developmental delay, brain mal... | Identification and Treatment of Biological Clock Dysfunction in Optic Nerve Hypoplasia | [
{
"description": "Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)",
"name": "Melatonin",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"type": "Dietary Supplement"
},
{
"description": "Oral administration before bed. 6 week duration.",
... | [
{
"design_group_description": "Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"interventio... | [
"Biological Clock Dysfunction",
"Optic Nerve Hypoplasia"
] | [
"Yale University"
] | [
"Children's Hospital Los Angeles"
] | [
[
{
"name": "褪黑素",
"lang": "CN"
},
{
"name": "Melatonin",
"lang": "EN"
},
{
"name": "メラトニン",
"lang": "JP"
}
]
] | null |
NCT07079631 | [
{
"id_field": "org_study_id",
"id_value": [
"BNT314-02"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2025-521768-36-00"
]
}
] | https://clinicaltrials.gov/study/NCT07079631 | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer | This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorectal cancer (mCRC).<br... | A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer | [
{
"description": "Intravenous (IV) infusion",
"name": "BNT314",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "IV infusion",
"name": "BNT327",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"des... | [
{
"design_group_description": "Up to 5 dose levels of BNT314. One or two dose levels of BNT327.",
"design_group_title": "Phase 1 (Part A): BNT314 (escalating dose levels) + BNT327",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"inter... | [
"Metastatic Colorectal Cancer"
] | [
"BioNTech SE"
] | [
"Genmab A/S"
] | [
[
{
"name": "普密妥米单抗",
"lang": "CN"
},
{
"name": "Pumitamig",
"lang": "EN"
}
],
[
{
"name": "DuoBody-EpCAMx4-1BB",
"lang": "EN"
}
]
] | null |
NCT06370598 | [
{
"id_field": "org_study_id",
"id_value": [
"TP-122"
]
},
{
"id_field": "acronym",
"id_value": [
"RECOVER"
]
}
] | https://clinicaltrials.gov/study/NCT06370598 | Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia | Given the challenges of treating complex cases of VAP caused by P. aeruginosa and K. pneumoniae, TechnoPhage developed a bacteriophage cocktail (TP-122) against those pathogens, aiming to provide a hospital-based add-on therapy to the SoC including antibiotic therapy, administered by nebulization. TP-122 is a bacteriop... | A Randomized, Parallel, Open-Label, Phase 1/2a Study to Assess the Safety and Tolerability of Multiple Doses of the Bacteriophage Cocktail TP-122 (Component TP-122A), for the Treatment of Ventilator-Associated Pneumonia | [
{
"description": "Bacteriophage cocktail targeting Psa",
"name": "TP-122A",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Enrolled subjects in the TP-122A+SoC arm will receive IP every 8 hours for 7 days by nebulization and will be followed-up for 28 days after the last IP administration.",
"design_group_title": "TP-122A with SOC",
"design_group_type": "Experimental",
"design_group_type_n... | [
"Pneumonia, Ventilator-Associated"
] | [
"TechnoPhage SA"
] | [
"Vectorb2B"
] | [
[
{
"name": "Bacteriophage Cocktail(TechnoPhage SA)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RECOVER"
}
] |
NCT04116658 | [
{
"id_field": "org_study_id",
"id_value": [
"EOGBM1-18"
]
},
{
"id_field": "acronym",
"id_value": [
"ROSALIE"
]
}
] | https://clinicaltrials.gov/study/NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma | The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma. | A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma | [
{
"description": "Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase",
"name": "Multiple dose of EO2401",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab",
"design_group_title": "Cohort 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Glioblastoma, Adult"
] | [
"Enterome SA"
] | [
"Labcorp Drug Development, Inc."
] | [
[
{
"name": "Tindupepimut",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "20a24a5e355eaa5d8d0ea5aa58e230e8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8e844ad2582d4032e829453399852020",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "EO2... |
NCT02734004 | [
{
"id_field": "org_study_id",
"id_value": [
"D081KC00001"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2015-004005-16"
]
},
{
"id_field": "acronym",
"id_value": [
"MEDIOLA"
]
}
] | https://clinicaltrials.gov/study/NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investig... | A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors | [
{
"description": "Olaparib",
"name": "Olaparib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "MEDI4736",
"name": "MEDI4736",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Bevacizuma... | [
{
"design_group_description": "Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1",
"design_group_title": "Arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3544... | [
"Ovarian",
"Breast",
"SCLC",
"Gastric Cancers"
] | [
"AstraZeneca PLC"
] | [
"IQVIA Holdings, Inc."
] | [
[
{
"name": "奥拉帕利",
"lang": "CN"
},
{
"name": "Olaparib",
"lang": "EN"
},
{
"name": "オラパリブ",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "ベバ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "345a9425a2923a39e282922245e85e20",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "558aa224e9844ea5220585aa8822ead9",
"s... |
NCT02408744 | [
{
"id_field": "org_study_id",
"id_value": [
"Pirfenidona 001"
]
}
] | https://clinicaltrials.gov/study/NCT02408744 | Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease | The aim of this study was to evaluate the impact in safety and efficacy of a new formulation of prolonged-released Pirfenidone in the progression of renal damage in patients with Chronic kidney Disease (CKD). | Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease | [
{
"description": "Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and es... | [
{
"design_group_description": "Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.",
"design_group_title": "Pirfenidone",
"design_group_type": "Experimental",
"design_group_type_normalized_id... | [
"Fibrosis",
"Chronic Kidney Disease"
] | [
"University of Guadalajara"
] | [
"Cell Therapy And Technology, S.a. De C.v."
] | [
[
{
"name": "吡非尼酮",
"lang": "CN"
},
{
"name": "Pirfenidone",
"lang": "EN"
},
{
"name": "ピルフェニドン",
"lang": "JP"
}
]
] | null |
NCT05834296 | [
{
"id_field": "org_study_id",
"id_value": [
"ALZN002-01"
]
}
] | https://clinicaltrials.gov/study/NCT05834296 | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type. | Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer's Dementia | [
{
"description": "The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide... | [
{
"design_group_description": "ALZN002 (autologous DCs pulsed with E22W mutant peptide).",
"design_group_title": "Active",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Th... | [
"Alzheimer Disease"
] | [
"Alzamend Neuro, Inc."
] | [
"Biorasi LLC"
] | [
[
{
"name": "ALZN002",
"lang": "EN"
}
]
] | null |
NCT00809237 | [
{
"id_field": "org_study_id",
"id_value": [
"NS 01/03/08"
]
},
{
"id_domain": "NHG Doman Specific Review Board",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"2008/00196"
]
}
] | https://clinicaltrials.gov/study/NCT00809237 | Hydroxychloroquine and Gefitinib to Treat Lung Cancer | Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality in men and women in Singapore.Chemotherapy and biologically targeted agents can extend survival only modestly for these patients; therefore, discovery of novel ways to prolong the disease course is a top research priority.<br/>The epidermal... | A Phase II With a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of Hydroxychloroquine and Gefitinib in Advanced Non-Small Cell Lung Cancer | [
{
"description": "Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose",
"name": "Gefitinib, Hydroxychloroquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Iressa"
],
"type": "Drug"
}
] | [
{
"design_group_description": "For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.<br/>After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg ... | [
"Non-small Cell Lung Cancer"
] | [
"National University Hospital"
] | [
"The General Hospital Corp.",
"AstraZeneca PLC"
] | [
[
{
"name": "硫酸羟氯喹",
"lang": "CN"
},
{
"name": "Hydroxychloroquine Sulfate",
"lang": "EN"
},
{
"name": "ドロキシクロロキン硫酸塩",
"lang": "JP"
}
],
[
{
"name": "吉非替尼",
"lang": "CN"
},
{
"name": "Gefitinib",
"lang": "EN"
},
... | null |
NCT05460273 | [
{
"id_field": "org_study_id",
"id_value": [
"D9266C00001"
]
},
{
"id_field": "secondary_id",
"id_value": [
"D9266C00001"
]
}
] | https://clinicaltrials.gov/study/NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). "Advanced" usually means that the cancer keeps growing even with treatment. The cancer may also be "metastatic", which means that it has spread to other parts of the body or the surrou... | Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02) | [
{
"description": "Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.",
"name": "Datopotamab Deruxtecan (Dato-DXd)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"DS-1062a"
],
"type": "Drug"
}
] | [
{
"design_group_description": "This single-arm study consists of multiple cohorts, divided by indication.",
"design_group_title": "Dato-DXd Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interve... | [
"Carcinoma, Non-Small-Cell Lung",
"Triple Negative Breast Cancer"
] | [
"AstraZeneca PLC"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "德达博妥单抗",
"lang": "CN"
},
{
"name": "Datopotamab Deruxtecan",
"lang": "EN"
},
{
"name": "ダトポタマブ デルクステカン（遺伝子組換え）（JAN）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "25538d53ee42082eea248935e3322d32",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8a3822a89959e44809a9a5ee9e8e2522",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT04818203 | [
{
"id_field": "org_study_id",
"id_value": [
"SB-FC-001"
]
}
] | https://clinicaltrials.gov/study/NCT04818203 | A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet | This study is a phase 1/2 clinical trial to evaluate the safety and efficacy of administering clusters of autologous dermal fibroblasts to subjects with periorbital wrinkles on both sides.<br/>If subjects who have signed the Informed consent form voluntarily are enrolled in this study, they will be tested for eligibili... | A Single Center, Randomized, Evaluator and Subject Blind, Placebo Controlled, Parallel, Phase 1/2 Study for the Anti-wrinkle Efficacy Assessment and Safety Evaluation by Treating Cluster of Autologous Dermal Fibroblasts, 3D-F in Patients With Bilateral Crow's Feet | [
{
"description": "Dose: 1 x 10^7 cells/1 mL/vial",
"name": "Clusters of Autologous Dermal Fibroblasts",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"3D-F",
"FECS-DF"
],
"single_or_multi": "single_drug",
"type": "Biological"
},
{
"description... | [
{
"design_group_description": "Participants receive 1 mL of clusters of autologous dermal fibroblast to three spots around the left eye and three spots around the right eye along the periorbital wrinkles on both sides, perpendicularly to the wrinkles.",
"design_group_title": "Test Group",
"design_group_... | [
"Crow's Feet"
] | [
"S.Biomedics Co., Ltd."
] | [
"Dt&SanoMedics Co. Ltd."
] | [
[
{
"name": "Clusters of Autologous Dermal Fibroblasts(S.Biomedics)",
"lang": "EN"
}
]
] | null |
NCT00510497 | [
{
"id_field": "org_study_id",
"id_value": [
"Riddler 055794"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5U19AI055794"
]
}
] | https://clinicaltrials.gov/study/NCT00510497 | Autologous Dendritic Cell Vaccine in HIV1 Infection | This study aims to look at the safety and tolerability of immunization with dendritic cell vaccine prepared using the patient's own cells and virus. It also aims to explore the virologic efficacy of the vaccine as determined by a decrease in the viral load 12 weeks after analytic treatment interruption. | Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells | [
{
"description": "Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption",
"name": "Autologous HIV-1 ApB DC Vaccine",
"normalized_type": "30faef638ae74c... | [
{
"design_group_description": "Subjects who will receive ApB Dendritic cell vaccine",
"design_group_title": "Autologous HIV-1 ApB DC Vaccine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interventi... | [
"HIV Infections"
] | [
"University of Pittsburgh"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "Dendritic Cell Vaccine(Baylor Research Institute)",
"lang": "EN"
}
]
] | null |
NCT00358319 | [
{
"id_field": "org_study_id",
"id_value": [
"MCC-13991"
]
}
] | https://clinicaltrials.gov/study/NCT00358319 | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | This is a Phase I study looking at the combination of Valproic Acid (VPA) and Karenitecin to treat patients with metastatic malignant melanoma. We will find the dose-limiting toxicity (DLT) and the highest dose (maximum tolerated dose) of this combination treatment that has acceptable side effects and recommend a Phase... | Phase I/II Trial of Valproic Acid and Karenitecin for Metastatic Malignant Melanoma | [
{
"name": "Karenitecin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Valproic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"VPA"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Dose escalation phase",
"design_group_title": "Phase I",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Valproic Acid",
"intervention_other_... | [
"Malignant Melanoma"
] | [
"H. Lee Moffitt Cancer Center & Research Institute, Inc."
] | [
"BioNumerik Pharmaceuticals, Inc."
] | [
[
{
"name": "可司替康",
"lang": "CN"
},
{
"name": "Cositecan",
"lang": "EN"
}
],
[
{
"name": "丙戊酸",
"lang": "CN"
},
{
"name": "Valproic Acid",
"lang": "EN"
}
]
] | null |
NCT06284486 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-0794"
]
},
{
"id_domain": "NCI-CTRP Clinical Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2024-01721"
]
}
] | https://clinicaltrials.gov/study/NCT06284486 | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML. | A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | [
{
"description": "Given by PO",
"name": "Venetoclax",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ABT-199",
"GDC-0199"
],
"type": "Drug"
},
{
"description": "Given by PO",
"name": "Revumenib",
"normalized_type": "3d1aa88261d64c038413723... | [
{
"design_group_description": "Participants may receive the combination of venetoclax and revumenib for up to 1 year, and then 1 more year of venetoclax alone. You will no longer be able to take the study drug(s) if the disease gets worse or if intolerable side effects occur. Participants will take venetoclax b... | [
"Acute Myeloid Leukemia"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Syndax Pharmaceuticals, Inc.",
"AbbVie, Inc."
] | [
[
{
"name": "维奈克拉",
"lang": "CN"
},
{
"name": "Venetoclax",
"lang": "EN"
},
{
"name": "ベネトクラクス",
"lang": "JP"
}
],
[
{
"name": "瑞维美尼",
"lang": "CN"
},
{
"name": "Revumenib",
"lang": "EN"
}
]
] | null |
NCT01098357 | [
{
"id_field": "org_study_id",
"id_value": [
"BC1-CT1"
]
}
] | https://clinicaltrials.gov/study/NCT01098357 | Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer | This is an open-label, active-control, multicentre, parallel group, randomised and dose-finding efficacy and safety study.<br/>Compare the efficacy and safety of BioChaperone PDGF-BB applied at 12.5 µg/cm² every two days for up to 20 weeks to becaplermin gel (Regranex® Gel 0.01%) applied daily for up to 20 weeks for th... | A Phase I/II, Multicentre, Randomised, Controlled, and Open-label Trial Comparing the Efficacy and Safety of Three Dose Regimens of BioChaperone PDGF-BB to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer | [
{
"description": "BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks",
"name": "Biochaperone PDGF-BB Low dose",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BC low dose"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.",
"design_group_titl... | [
"Diabetic Foot Ulcers"
] | [
"Virchow Group"
] | [
"Adocia SA"
] | [
[
{
"name": "贝卡普勒明生物类似药(Adocia)",
"lang": "CN"
},
{
"name": "Becaplermin biosimilar(Adocia)",
"lang": "EN"
}
]
] | null |
NCT05230810 | [
{
"id_field": "org_study_id",
"id_value": [
"01AB21- PIK3CA"
]
},
{
"id_field": "secondary_id",
"id_value": [
"01AB21- PIK3CA"
]
}
] | https://clinicaltrials.gov/study/NCT05230810 | Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. | Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer. | This is a Multicenter, Single Arm, Open-label, run-in Phase Ib / Roll-over Phase II Study of Tucatinib in Combination With Alpelisib in Subjects With PIK3CA-mutant HER2-positive Locally Advanced Unresectable or Metastatic Breast Cancer. | [
{
"description": "Orally twice a day",
"name": "Alpelisib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Piqray"
],
"type": "Drug"
},
{
"description": "Orally once a day",
"name": "Tucatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_description": "In phase Ib, the tolerability of tucatinib and alpelisib combination will be confirmed and maximum tolerated dose determined. Therapy will be administered in 28 day cycles of tucatinib 300 mg PO BID and alpelisib 250 mg PO daily (dose level 1). Treatment will continue until unacce... | [
"HER2-positive Metastatic Breast Cancer"
] | [
"CRITERIUM, Inc."
] | [
"Novartis AG",
"Seagen, Inc."
] | [
[
{
"name": "氟维司群",
"lang": "CN"
},
{
"name": "Fulvestrant",
"lang": "EN"
},
{
"name": "フルベストラント",
"lang": "JP"
}
],
[
{
"name": "阿培利司",
"lang": "CN"
},
{
"name": "Alpelisib",
"lang": "EN"
}
],
[
{
... | null |
NCT00237627 | [
{
"id_field": "org_study_id",
"id_value": [
"LCCC 2020"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UNC-LCCC-2020"
]
},
{
"id_domain": "PDQ number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CDR0000368767"
]
... | https://clinicaltrials.gov/study/NCT00237627 | Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer | RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving doxor... | A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies | [
{
"description": "PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be da... | [
{
"design_group_description": "Doxil + PS-341",
"design_group_title": "Part 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Doxil will be administered at a dose of 30 mg... | [
"Breast Cancer",
"Leukemia",
"Lymphoma",
"Multiple Myeloma and Plasma Cell Neoplasm",
"Ovarian Cancer",
"Unspecified Adult Solid Tumor, Protocol Specific"
] | [
"Lineberger Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸多柔比星脂质体",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride liposomal",
"lang": "EN"
}
],
[
{
"name": "硼替佐米",
"lang": "CN"
},
{
"name": "Bortezomib",
"lang": "EN"
},
{
"name": "ボルテゾミブ",
"lang": "JP"... | null |
NCT00352235 | [
{
"id_field": "org_study_id",
"id_value": [
"KRN7000 HCV"
]
}
] | https://clinicaltrials.gov/study/NCT00352235 | Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection | Phase I/II trial of KRN7000 in patients with chronic hepatitis C.<br/>Study objectives: To evaluate and compare the safety and tolerability of 3 ascending doses of a-GalCer.<br/>The primary efficacy parameter: HCV-RNA response at the end of treatment. Secondary efficacy parameter: Serum ALT response. Further objectives... | Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection | [
{
"name": "KRN7000",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Chronic Hepatitis C"
] | [
"Foundation for Liver Research"
] | [
"Kyowa Kirin Co., Ltd."
] | [
[
{
"name": "KRN-7000 liposomal",
"lang": "EN"
}
]
] | null |
NCT02851472 | [
{
"id_field": "org_study_id",
"id_value": [
"FDA IND 126254"
]
},
{
"id_field": "acronym",
"id_value": [
"iNO-TRAGI"
]
}
] | https://clinicaltrials.gov/study/NCT02851472 | Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO | The investigators seek to determine whether providing inhaled nitric oxide (iNO; a vasodilator) will improve the delivery of oxygen to the brain, kidney and intestines of preterm neonates during and after the subject receives a packed red blood cell transfusion (PRBC) for anemia vs. baseline period. The investigators w... | Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGAN) Neonates Using iNO | [
{
"description": "Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.",
"name": "Inhaled Nitric Oxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"o... | [
{
"design_group_description": "iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring",
"design_group_title": "Inhaled Nitric Oxide",
"design_group_type": "Experimental",
"design_group_type_normaliz... | [
"Anemia"
] | [
"New York Medical College"
] | [
"Stony Brook University",
"East Carolina University",
"New York University",
"Baystate Medical Center"
] | [
[
{
"name": "一酸化窒素",
"lang": "CN"
},
{
"name": "Nitric oxide (inhaled)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "iNO-TRAGI"
}
] |
NCT04669587 | [
{
"id_field": "org_study_id",
"id_value": [
"ENZENO-C-101"
]
},
{
"id_field": "acronym",
"id_value": [
"ENZENO"
]
}
] | https://clinicaltrials.gov/study/NCT04669587 | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) | For patients with ER-positive, HER2-negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. These patients showed good response to endocrine therapy.<br/>Fulvestrant, the approved SERD as monotherapy or in combination with CDK4/6 inhibitors, showed superior clinical be... | A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of ZB716 as Monotherapy and in Combination With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | [
{
"description": "Pharmaceutical form: capsule Route of administration: oral",
"name": "ZB716",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Borestrant"
],
"type": "Drug"
},
{
"description": "Pharmaceutical form: capsule Route of administration: oral"... | [
{
"design_group_description": "Cohorts will follow a 3+3 study design. Approx. 3 to 6 subjects will be enrolled in each dose cohort (6 subjects in Cohort A6; food-effect evaluation). (Dose levels: 50, 100, 200, 300, 400 mg, orally QD in a 28 day cycle) The overall DLT observation period of ZB716 monotherapy wil... | [
"Estrogen Receptor-Positive",
"HER2-Negative",
"Locally Advanced Breast Cancer",
"Metastatic Breast Cancer"
] | [
"EnhancedBio USA Inc."
] | [
"Zeno Pharmaceuticals, Inc."
] | [
[
{
"name": "ZB-716",
"lang": "EN"
}
],
[
{
"name": "哌柏西利",
"lang": "CN"
},
{
"name": "Palbociclib",
"lang": "EN"
},
{
"name": "パルボシクリブ",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ENZENO"
}
] |
NCT03750071 | [
{
"id_field": "org_study_id",
"id_value": [
"VXM01-AVE-04-INT"
]
}
] | https://clinicaltrials.gov/study/NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | VXM01 in combination with avelumab in n=30 patients with progressive glioblastoma following standard treatment, with or without second surgery | An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery | [
{
"description": "Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid",
"name": "VXM01",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Investigational VEGFR-2 DNA Vaccine"
],
"type": "Biological"
},
{
"description": "Monoclonal anti-PD-L1 An... | [
{
"design_group_description": "Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab",
"design_group_title": "VXM01/Avelumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3... | [
"Recurrent Glioblastoma"
] | [
"Vaximm AG"
] | [
"Pfizer Inc.",
"Merck KGaA"
] | [
[
{
"name": "阿维单抗",
"lang": "CN"
},
{
"name": "Avelumab",
"lang": "EN"
},
{
"name": "アベルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "VXM-01",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "3d2359ea5d23eaeede82a228ae2d4025",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "42a55e49e2852a222ee25555028d0ee2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "KS0... |
NCT04216849 | [
{
"id_field": "org_study_id",
"id_value": [
"DFSC-2019(CR)-06"
]
}
] | https://clinicaltrials.gov/study/NCT04216849 | Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy | The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16 weeks of follow-up.To observe the efficacy and safety of umbilical cord mesenchymal stem cell infusion in Chinese patients with type 2 dia... | Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy | [
{
"description": "human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group",
"name": "human umbilical cord mesenchymal stem cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Saline solution co... | [
{
"design_group_description": "The volunteers of the experimental group will be given peripheral intravenously a dose of 1.5*10^6/kg human umbilical cord mesenchymal stem cells at 0,8,16,24,32 week.",
"design_group_title": "experimental group",
"design_group_type": "Experimental",
"design_group_type... | [
"Type 2 Diabetes With Renal Manifestations"
] | [
"Shanghai East Hospital"
] | [
"Chinese People's Liberation Army General Hospital"
] | [
[
{
"name": "Umbilical Cord Mesenchymal Stem Cells(Shanghai East Hospital)",
"lang": "EN"
}
]
] | null |
NCT04444674 | [
{
"id_field": "org_study_id",
"id_value": [
"ChAdOx1 nCoV-19_ZA_phI/II v4.1"
]
}
] | https://clinicaltrials.gov/study/NCT04444674 | COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection | A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years living with and without HIV in South Africa. The vaccine or placebo will be administered via an... | An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV | [
{
"description": "Dose of 5-7.5x10^10vp of ChAdOx1 nCoV-19",
"name": "ChAdOx1 nCoV-19",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Normal saline 0.9% as placebo",
"name": "Normal saline 0.9%",
"normalized_type": "30faef638ae74cc79... | [
{
"design_group_description": "Participants (HIV-negative) will receive two doses of 5-7.5x10^10 vp ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart. Participants, investigators and outcome assessors will be blinded to intervention. Participants will have 11 routine visits over a 12 month p... | [
"Coronavirus"
] | [
"University of Oxford"
] | [
"Gates Foundation (United States)",
"The Medical Research Council",
"Wits Health Consortium",
"University of the Witwatersrand"
] | [
[
{
"name": "COVID-19 Vaccine (ChAdOx1-S [recombinant])(AstraZeneca Plc)",
"lang": "EN"
},
{
"name": "コロナウイルス（SARS-CoV-2）ワクチン（遺伝子組換えサルアデノウイルスベクター）(AstraZeneca Plc)",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "29aae025ad98498a2e9a0258ea854a24",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "9500525208e2d5a905402248298dd58e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT01935635 | [
{
"id_field": "org_study_id",
"id_value": [
"2014ZX10002002-002"
]
}
] | https://clinicaltrials.gov/study/NCT01935635 | A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB | The purpose of this study is to investigate whether HB-Vac Activated-DCs Combined With Peg-IFN or NAs has more efficacy than Peg-IFN or NAs alone in the treatment of chronic hepatitis B patients | A Clinical Trial on Hepatitis B Vaccine Activated-DCs Combined With Peg-interferon or Nucleotide Analogs in Chronic Hepatitis B | [
{
"description": "HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;",
"name": "HPDCs-T immune therapy",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"HBsAg Pulse DCs-T",
... | [
{
"design_group_description": "HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks",
"design_group_title": "HPDCs-T immune therapy combined with... | [
"Chronic Hepatitis B"
] | [
"The Third Affiliated Hospital, Sun Yat-Sen University"
] | [
"Ruijin Hospital",
"Yunnan No. 2 People's Hospital"
] | [
[
{
"name": "恩替卡韦",
"lang": "CN"
},
{
"name": "Entecavir",
"lang": "EN"
},
{
"name": "エンテカビル水和物",
"lang": "JP"
}
]
] | null |
NCT06862817 | [
{
"id_field": "org_study_id",
"id_value": [
"Aloevera & benzydmin on RIOM"
]
}
] | https://clinicaltrials.gov/study/NCT06862817 | Comparison Between the Effect of Aloe Vera and Benzydamine Hydrochloride Mouth Gel on Prevention of Pain and Progression of Radiation-induced Oral Mucositis | Oral mucositis, a painful inflammation and ulceration of the mucous membranes in the mouth, is commonly seen in patients undergoing chemotherapy or radiation therapy. Effective management of this condition is crucial to reduce pain, promote healing, and maintain oral function.<br/>Benzydamine mouth gel is a non-steroid... | Comparison Between the Effect of Aloe Vera and Benzydamine Hydrochloride Mouth Gel on Radiation-induced Oral Mucositis (Randomized Clinical Trial) | [
{
"description": "Aloe vera mouthgel not only as a potent agent for prevention mucositis, but also as a prevention of candidiasis in patients undergoing radiotherapy of head and neck with its antifungal and immunomodulation properties",
"name": "Aloe vera gel",
"normalized_type": "3d1aa88261d64c03841372... | [
{
"design_group_description": "found that benzydamine mouth rinses and gels could prevent or reduce the severity of oral mucositis.",
"design_group_title": "benzydamine hydrochloride mouth gel",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a... | [
"Radiation Indused Oral Mucositis"
] | [
"Minia University"
] | [
"Faculty Of Medicine Minia University"
] | [
[
{
"name": "芦荟提取物",
"lang": "CN"
},
{
"name": "Aloe vera extract",
"lang": "EN"
}
],
[
{
"name": "盐酸苄达明",
"lang": "CN"
},
{
"name": "Benzydamine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT03981549 | [
{
"id_field": "org_study_id",
"id_value": [
"TRUST"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1UG1EY026876-01A1"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1UG... | https://clinicaltrials.gov/study/NCT03981549 | Treatment of Central Retinal Vein Occlusion Using Stem Cells Study | This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half wi... | Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion | [
{
"description": "Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.",
"name": "Autologous Bone Marrow CD34+ Stem Cells",... | [
{
"design_group_description": "At baseline: Bone marrow aspiration followed by intravitreal injection of CD34+ cells.<br/>At 6 months: Sham bone marrow aspiration and sham intravitreal injection.",
"design_group_title": "Immediate Cellular Therapy / Deferred Sham Therapy",
"design_group_type": "Active C... | [
"Central Retinal Vein Occlusion"
] | [
"The Emmes Co. LLC"
] | [
"University of California, Davis",
"National Eye Institute"
] | [
[
{
"name": "Autologous Bone Marrow CD34+ Stem Cells (Emmes)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "45ddda9a2232d4245e5280988928e22a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TRUST"
}
] |
NCT00004070 | [
{
"id_field": "org_study_id",
"id_value": [
"99-081"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA006516"
]
},
{
"id_field": "secondary_id",
"id_value": [
"VALENTIS-DFCI-99081"
]
},
{
"id_field"... | https://clinicaltrials.gov/study/NCT00004070 | Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer | Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to make the body build an immune response to kill more tumor cells. | A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) | [
{
"name": "IL-12",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"CLMF",
"Interleukin-12 gene",
"NFSK",
"P35"
],
"type": "Biological"
}
] | [
{
"design_group_description": "The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.",
"design_group_title": "IL-12 Injection 3mg/ml [Phase I]",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf6... | [
"Head and Neck Cancer"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"National Cancer Institute"
] | [
[
{
"name": "IL-12 gene therapy(Dana-Farber Cancer Institute/Valentis)",
"lang": "EN"
}
]
] | null |
NCT04742634 | [
{
"id_field": "org_study_id",
"id_value": [
"202103255"
]
}
] | https://clinicaltrials.gov/study/NCT04742634 | Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant | The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS) patients with persistent mutations (molecular MRD). To detect molecular MRD, the investiga... | A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant | [
{
"description": "* DEC-C will be provided by Taiho Pharmaceuticals.<br/>* Cycle 1 Day 1 may take place between Day 42 & Day 100 post-transplant.",
"name": "DEC-C",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ASTX727",
"INQOVI®",
"decitabine + cedazuridi... | [
{
"design_group_description": "* Bone marrow biopsy & MyeloSeq-HD will be obtained on Day 30 post-transplant. MRD positivity is defined as the presence of at least one somatically acquired mutation detected prior to transplant that persists at Day 30 post-transplant with a variant allele frequency of ≥ 0.2%. MR... | [
"Myelodysplastic Syndromes"
] | [
"Washington University School of Medicine"
] | [
"Taiho Oncology, Inc."
] | [
[
{
"name": "地西他滨/西达尿苷",
"lang": "CN"
},
{
"name": "Decitabine/Cedazuridine",
"lang": "EN"
}
]
] | null |
NCT03568422 | [
{
"id_field": "org_study_id",
"id_value": [
"I236"
]
}
] | https://clinicaltrials.gov/study/NCT03568422 | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer. One of the standard types of chemotherapy is a drug called paclitaxel (Taxol) given in a low dose every week for three out of four weeks.<br/>CFI-402257 is a new type of drug fo... | A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | [
{
"description": "Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 & 16",
"name": "CFI-402257",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "80 mg/m2 IV days 1, 8 & 15 every 28 days",
"name": "Paclitaxel",
"normalized_type": "3d... | [
{
"design_group_description": "Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days",
"design_group_title": "CFI-402257 + Paclitaxel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3544... | [
"Breast Cancer"
] | [
"Canadian Cancer Trials Group"
] | [
"The Canadian Breast Cancer Foundation",
"Stand Up To Cancer",
"Ontario Institute for Cancer Research"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "CFI-402257",
"lang": "EN"
}
]
] | null |
NCT02363491 | [
{
"id_field": "org_study_id",
"id_value": [
"OPN-305-106"
]
}
] | https://clinicaltrials.gov/study/NCT02363491 | A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome | The dose-confirming part of this study, comprising at least 10 patients is designed as a single center, prospective, single arm, open label in patients who have failed or are unresponsive to Azacitidine (AZA) or Decitabine (they may also have additionally failed an Erythropoiesis Stimulating Agent (ESA) followed by a d... | A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line or Third-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS) | [
{
"description": "For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.",
"name": "OPN-305",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "OPN-305",
"design_group_title": "OPN-305",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "For the dose confirming part of the study, patients... | [
"Myelodysplastic Syndrome"
] | [
"Opsona Therapeutics Ltd."
] | [
"The University of Texas MD Anderson Cancer Center",
"Montefiore Medical Center",
"H. Lee Moffitt Cancer Center & Research Institute, Inc."
] | [
[
{
"name": "托拉利单抗",
"lang": "CN"
},
{
"name": "Tomaralimab",
"lang": "EN"
}
]
] | null |
NCT02494921 | [
{
"id_field": "org_study_id",
"id_value": [
"145515"
]
},
{
"id_domain": "Clinical Trials Reporting Program",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-01797"
]
}
] | https://clinicaltrials.gov/study/NCT02494921 | LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of docetaxel (75 mg/m2 IV q21 days) and prednisone (5mg orally BID) in ... | A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer | [
{
"description": "Given IV",
"name": "Docetaxel-PNP",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Docetaxel Injection",
"Taxotere"
],
"type": "Drug"
},
{
"description": "Given Orally",
"name": "Ribociclib",
"normalized_type": "3d1aa8826... | [
{
"design_group_description": "The starting cohort dose level (1) for docetaxel will be 75 mg/m2, administered on day 1 of each cycle. Prednisone will be fixed at 5 mg twice a day. The starting dose level and schedule for ribociclib will begin at 200 mg orally once daily, starting on day 1 of the 21-day cycle. ... | [
"Prostate Cancer"
] | [
"The University of California, San Francisco"
] | [
"Novartis AG"
] | [
[
{
"name": "琥珀酸瑞波西利",
"lang": "CN"
},
{
"name": "Ribociclib Succinate",
"lang": "EN"
}
],
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
],
[
{
"name": "非格司亭 （安进）",
"lang": "CN"
},... | [
{
"identifier_source": [
{
"code": "4592229a2ea24ae5552e8528a2859da2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "c15-149"
}
] |
NCT01486810 | [
{
"id_field": "org_study_id",
"id_value": [
"#6154"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P50DA009236-18"
]
},
{
"id_field": "acronym",
"id_value": [
"Vyvance"
]
}
] | https://clinicaltrials.gov/study/NCT01486810 | Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence | The proposed protocol is an open-label pilot study of the treatment of cocaine dependence using lisdexamfetamine (LDX), a prodrug of d-amphetamine. The investigators plan to enroll 12 patients in an eight-week open-label trial to obtain preliminary data regarding the safety, tolerability, and potential utility of lisde... | Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence | [
{
"description": "Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks",
"name": "Lisdexamfetamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Vyvanc... | [
{
"design_group_description": "Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using ... | [
"Cocaine Dependence"
] | [
"The New York State Psychiatric Institute"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "二甲磺酸赖右苯丙胺",
"lang": "CN"
},
{
"name": "Lisdexamfetamine Dimesylate",
"lang": "EN"
},
{
"name": "リスデキサンフェタミンメシル酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "299ea900d5aa2a8a902d4839e584a4e5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Vyvance"
}
] |
NCT04111497 | [
{
"id_field": "org_study_id",
"id_value": [
"RG1005365"
]
},
{
"id_domain": "NCI / CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2019-03244"
]
},
{
"id_domain": "Fred Hutch/University of Washington Cancer Consortium",
... | https://clinicaltrials.gov/study/NCT04111497 | Glasdegib for Chronic Graft-Versus-Host Disease | This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease. | A Single-Arm, Open-Label, Phase I/II Study of Glasdegib for Sclerotic Chronic Graft-Vs-Host Disease | [
{
"description": "Given PO",
"name": "Glasdegib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"1095173-27-5",
"PF 04449913",
"PF-04449913",
"PF04449913"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients receive glasdegib PO QD on days 1-28. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (glasdegib)",
"design_group_type": "Experimental",
"design_group_type_norma... | [
"Chronic Graft Versus Host Disease",
"Fasciitis"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"Pfizer Inc."
] | [
[
{
"name": "马来酸格拉吉布",
"lang": "CN"
},
{
"name": "Glasdegib Maleate",
"lang": "EN"
}
]
] | null |
NCT02452281 | [
{
"id_field": "org_study_id",
"id_value": [
"C-100-41"
]
},
{
"id_domain": "UTHSC-H CPHS (IRB)",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"HSC-MS-14-0070"
]
}
] | https://clinicaltrials.gov/study/NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is safe and effective in the treatment of advanced melanoma. HSPPC-96 is an investigational vaccine created from tissue from the patient's tumor. The vaccine is designed to capture the cancer's "fingerprint." Injection of the vac... | Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma | [
{
"description": "3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.",
"name": "ipilimumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Yervoy ®"
],
"type": "Drug"
},
{
"d... | [
{
"design_group_description": "* Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.<br/>* HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours foll... | [
"Melanoma"
] | [
"The University of Texas Health Science Center at Houston"
] | [
"Agenus, Inc."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Oncophage, NewVac adjuvanted(Agenus, Inc.)",
"lang": "EN"
}
]
] | null |
NCT03384524 | [
{
"id_field": "org_study_id",
"id_value": [
"The BEAT DME Study"
]
}
] | https://clinicaltrials.gov/study/NCT03384524 | Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME | This phase I/II trial is designed to provide proof of concept evidence that combination therapy can have a beneficial effect on DME and possibly prevent increases in retinal volume or progression of non-central DME into the central subfield of the macula. If a beneficial effect is apparent in this phase I/II study invo... | A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema | [
{
"description": "Administered daily",
"name": "Bromocriptine 2.5 MG",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Bromocriptine Mesylate"
],
"type": "Drug"
},
{
"description": "Administered daily",
"name": "Metoprolol 25 MG",
"normalized_typ... | [
{
"design_group_description": "A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)",
"design_group_title": "Combination regiment",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
... | [
"Diabetic Macular Edema"
] | [
"University of Southern California"
] | [
"Case Western Reserve University"
] | [
[
{
"name": "盐酸坦洛新",
"lang": "CN"
},
{
"name": "Tamsulosin Hydrochloride",
"lang": "EN"
},
{
"name": "タムスロシン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "甲磺酸溴隐亭",
"lang": "CN"
},
{
"name": "Bromocriptine Mesylate",
"lang": "E... | null |
NCT06492863 | [
{
"id_field": "org_study_id",
"id_value": [
"FT003-C101"
]
}
] | https://clinicaltrials.gov/study/NCT06492863 | Gene Therapy(FT-003) for Wet AMD | The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion. | A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With Wet AMD | [
{
"description": "Administered via intraocular injection.",
"name": "FT-003",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"type": "Genetic"
}
] | [
{
"design_group_description": "Low dose of FT-003",
"design_group_title": "FT003 Dose 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Administered via intraocular inject... | [
"Neovascular Age-related Macular Degeneration"
] | [
"Frontera Therapeutics, Inc."
] | [
"Peking Union Medical College Hospital",
"The First Affiliated Hospital of Soochow University",
"Beijing Hospital of the Ministry of Health"
] | [
[
{
"name": "FT-003",
"lang": "EN"
}
]
] | null |
NCT05507697 | [
{
"id_field": "org_study_id",
"id_value": [
"WuhanCH"
]
}
] | https://clinicaltrials.gov/study/NCT05507697 | Treatment With Human Umbilical Cord Mesenchymal Stem Cells for Refractory Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathy (DPN) is one of the most common chronic complications in type 2 diabetes, conventional drug therapy can only target a single pathogenesis but not treat Diabetic Peripheral Neuropathy (DPN) fundamentally. As a novel technique, stem cell transplantation provides a new option for patients wi... | Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Refractory Diabetic Peripheral Neuropathy | [
{
"description": "5 × 10^6 cells/mL, 1 mL per injection, each injection point is 2 cm apart ,1.0-1.5 cm deep, total amount of injection is estimated based on the surface area of the patient's lower limb",
"name": "HUC-MSCs",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"... | [
{
"design_group_description": "MSCs Participants will received i. m. HUC-MSCs both lower extremities",
"design_group_title": "Experimental",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention... | [
"Diabetic Peripheral Neuropathy Type 2"
] | [
"The Central Hospital Of Wuhan"
] | [
"Vcanbio Cell & Gene Technology Co., Ltd.",
"Wuhan Optics Valley Vcanbiopharma Co., Ltd."
] | [
[
{
"name": "人脐带源间充质干细胞(武汉光谷中源)",
"lang": "CN"
},
{
"name": "VUM-02",
"lang": "EN"
}
]
] | null |
NCT06940921 | [
{
"id_field": "org_study_id",
"id_value": [
"Zhang Tao"
]
}
] | https://clinicaltrials.gov/study/NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | The goal of this clinical trial is to see if high- and low-dose radiotherapy combined with immunotherapy can work in patients with advanced gastric, colorectal, and ovarian cancers with peritoneal metastases, and to learn about the safety of this new combination treatment modality. The main questions they aim to answer... | A Single-arm, Prospective Clinical Study of Low-dose Radiation Therapy (LDRT) Combined With Stereotactic Body Radiation Therapy (SBRT) and Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | [
{
"description": "Radiation: Stereotactic Body Radiation Therapy (SBRT)<br/>* Stereotactic Body Radiation Therapy (SBRT) will be performed first at a total dose of 20-50 Gy, delivered in 3-5 fractions of 6-10 Gy each. And the target area was specifically selected based on the location and size of the patient's ... | [
{
"design_group_description": "Patients in the experimental arm will receive stereotactic body radiation therapy (SBRT) to selected tumor sites and low-dose radiotherapy (LDRT) to the whole abdomen, followed by Cadonilimab immunotherapy.",
"design_group_title": "Whole abdominal LDRT combined with SBRT follo... | [
"Advanced Gastric Cancer",
"Advanced Colorectal Cancer",
"Advanced Ovarian Cancer",
"Peritoneal Metastasis"
] | [
"Chongqing Medical University /The First Affiliated Hospital/"
] | [
"Akeso Pharmaceuticals, Inc."
] | [
[
{
"name": "卡度尼利单抗",
"lang": "CN"
},
{
"name": "Cadonilimab",
"lang": "EN"
}
]
] | null |
NCT03232138 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY19040278"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01CA213123"
]
}
] | https://clinicaltrials.gov/study/NCT03232138 | Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers | This research study involves taking an experimental anti-cancer dietary supplement called Sulforaphane (SF) or a placebo (product without any supplement content) over a period of twelve months in order to determine if it is a useful dietary supplement for prevention of lung cancer in humans.<br/>The main goals of this ... | Randomized Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers | [
{
"description": "Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.",
"name": "Sulforaphane",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"other_name": [
"Avmacol®"
],
"type": "Dietary Supplement"
},
{
"description"... | [
{
"design_group_description": "Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane",
"design_group_title": "Sulforaphane (Study Drug)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b... | [
"Lung Cancer"
] | [
"University of Pittsburgh"
] | [
"National Cancer Institute"
] | [
[
{
"name": "磺胺葡聚糖",
"lang": "CN"
},
{
"name": "Sulforadex",
"lang": "EN"
}
]
] | null |
NCT06201234 | [
{
"id_field": "org_study_id",
"id_value": [
"ELEMENT GBG-114"
]
},
{
"id_field": "acronym",
"id_value": [
"ELEMENT"
]
}
] | https://clinicaltrials.gov/study/NCT06201234 | Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer | Trial design:<br/>Phase II, prospective, multi-center, randomized, open label, parallel group study in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutation, with 2:1 randomization into Arm A (olaparib + elacestrant) or arm B (olaparib). Treatment in either arm wil... | Phase II Study Evaluating the Addition of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), to Standard-of-care Olaparib in Patients With Hormone Receptor (HR)-Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer With gBRCA1/2 Mutations | [
{
"description": "Olaparib 600 mg orally daily and elacestrant 400 mg orally daily",
"name": "Olaparib + Elacestrant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Olaparib 600 mg orally daily",
"name": "Olaparib",
"normalized_type": "3d1... | [
{
"design_group_description": "Treatment will be given until disease progression, unacceptable toxicity, withdrawal of patient´s consent to study participation, or end of study.<br/>* Together with GnRH analogue in pre- and perimenopausal women, and in men, at least two weeks prior to treatment.<br/>* Elacestra... | [
"Hormone Receptor Positive HER-2 Negative Breast Cancer",
"Advanced or Metastatic Breast Cancer",
"BRCA1 Mutation",
"BRCA2 Mutation"
] | [
"GBG Forschungs GmbH"
] | [
"Stemline Therapeutics, Inc."
] | [
[
{
"name": "奥拉帕利",
"lang": "CN"
},
{
"name": "Olaparib",
"lang": "EN"
},
{
"name": "オラパリブ",
"lang": "JP"
}
],
[
{
"name": "艾拉司群",
"lang": "CN"
},
{
"name": "Elacestrant hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ELEMENT"
}
] |
NCT00937235 | [
{
"id_field": "org_study_id",
"id_value": [
"R01DA023507"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA023507"
]
}
] | https://clinicaltrials.gov/study/NCT00937235 | Treatment of Smoking Among Individuals With PTSD | This study will examine the effect of combining prolonged exposure, a cognitive-behavioral treatment program for post-traumatic stress disorder (PTSD) with medication (varenicline) and counseling treatments for smoking cessation. Subjects will be randomly assigned to a 3-month treatment of either: 1) varenicline and sm... | Treatment of Smoking Among Individuals With PTSD: A Phase II, Randomized Study of Varenicline and Cognitive Behavioral Therapy | [
{
"description": "1 mg tablets, orally, twice daily x 12 weeks",
"name": "Varenicline",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Chantix"
],
"type": "Drug"
},
{
"description": "15-minutes weekly counseling x 12 weeks, focused on medication adheren... | [
{
"design_group_description": "Prolonged Exposure + Varenicline + Medication Management Counseling",
"design_group_title": "Integrated Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Cigarette Smoking",
"Nicotine Dependence",
"Post-traumatic Stress Disorder",
"Tobacco Use Disorder"
] | [
"University of Pennsylvania"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "酒石酸伐尼克兰",
"lang": "CN"
},
{
"name": "Varenicline Tartrate",
"lang": "EN"
},
{
"name": "バレニクリン酒石酸塩",
"lang": "JP"
}
]
] | null |
NCT03126799 | [
{
"id_field": "org_study_id",
"id_value": [
"NCC-2016-0107"
]
},
{
"id_field": "acronym",
"id_value": [
"AvaTa"
]
}
] | https://clinicaltrials.gov/study/NCT03126799 | A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) | Korean data of treating EGFR mutation positive NSCLC patients with Erlotinib and Bevacizumab is significantly necessary for developing new standard treatment in first-line therapy in Korean EGFR mutant NSCLC patients.<br/>In this study, The investigators will investigate the efficacy and safety of Erlotinib and Bevaciz... | A Randomized Phase II Study of Erlotinib Alone Versus Erlotinib Plus Bevacizumab for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations | [
{
"description": "Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks",
"name": "Erlotinib plus Bevacizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tarceva plus Avastin"
],
"type": "Drug"
},
{
"description": "Erlo... | [
{
"design_group_description": "Standard therapy arm:<br/>Erlotinib 150mg. po, qd, daily, q 3weeks",
"design_group_title": "A: Erlotinib only",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"inter... | [
"EGFR Positive Non-small Cell Lung Cancer"
] | [
"National Cancer Center Korea"
] | [
"Roche Korea Co., Ltd."
] | [
[
{
"name": "盐酸厄洛替尼",
"lang": "CN"
},
{
"name": "Erlotinib Hydrochloride",
"lang": "EN"
},
{
"name": "エルロチニブ塩酸塩",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "22da32882d0d54222585a5a252aaa052",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "AvaTa"
}
] |
NCT05291390 | [
{
"id_field": "org_study_id",
"id_value": [
"PND7351"
]
}
] | https://clinicaltrials.gov/study/NCT05291390 | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) | A Phase 2a clinical trial on up to n=200 male and female subjects 18 years and over who were diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Subjects are randomised in approximately a 1:1 ratio to receive standard of care treatment plus either pyronaridine (PND) or placebo. Quality of... | A Phase 2a, Multi-centre, Randomised, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine as an Add-on Therapy in Adults With Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia | [
{
"description": "Via oral capsules.",
"name": "Pyronaridine Tetraphosphate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Placebo"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Standard of care treatment plus pyronaridine",
"design_group_title": "Standard of care treatment plus pyronaridine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"... | [
"Acute Myeloid Leukemia (AML)",
"Acute Lymphoblastic Leukemia (ALL)"
] | [
"Armaceutica, Inc."
] | [
"Ifakara Health Institute"
] | [
[
{
"name": "磷酸咯萘啶",
"lang": "CN"
},
{
"name": "Pyronaridine Phosphate",
"lang": "EN"
}
]
] | null |
NCT00941330 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00012969"
]
},
{
"id_domain": "Other",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"WCI1534-08"
]
}
] | https://clinicaltrials.gov/study/NCT00941330 | Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers | The patients are being asked to take part in this study because they have a hormone receptor-positive breast cancer (contains estrogen and/or progesterone receptors) and their doctor has told them that they have an option to receive chemotherapy or hormonal therapy before surgery. The purpose of this study is to assess... | Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24) | [
{
"description": "25 mg daily by mouth for 6 to 12 months.",
"name": "Exemestane",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Aromasin"
],
"type": "Drug"
},
{
"description": "Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times ... | [
{
"design_group_description": "ARM A: Patients will be treated with exemestane.",
"design_group_title": "A: Exemestane",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "25 m... | [
"Breast Cancer"
] | [
"Emory University"
] | [
"Pfizer Inc."
] | [
[
{
"name": "依西美坦",
"lang": "CN"
},
{
"name": "Exemestane",
"lang": "EN"
},
{
"name": "エキセメスタン",
"lang": "JP"
}
]
] | null |
NCT02145767 | [
{
"id_field": "org_study_id",
"id_value": [
"PRMT15"
]
}
] | https://clinicaltrials.gov/study/NCT02145767 | Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial | Miscarriages and preterm births are common and serious events affecting women, families, and healthcare systems on many levels. One of the risk factors for miscarriage and preterm birth is bleeding in the first trimester of pregnancy. Progesterone, a hormone that plays a key role during pregnancy, has been proposed as ... | Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial | [
{
"name": "Progesterone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.",
"design_group_title": "Progesterone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention... | [
"Miscarriage",
"Preterm Birth"
] | [
"The Jewish General Hospital"
] | [
"Canadian Institutes of Health Research"
] | [
[
{
"name": "黄体酮",
"lang": "CN"
},
{
"name": "Progesterone",
"lang": "EN"
},
{
"name": "プロゲステロン",
"lang": "JP"
}
]
] | null |
NCT05200260 | [
{
"id_field": "org_study_id",
"id_value": [
"SAT-1"
]
}
] | https://clinicaltrials.gov/study/NCT05200260 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer | A Prospective, Multicenter, Randomized Phase II Trial on Optimal Timing of Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | [
{
"description": "Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.",
"name": "Primary debulking surgery",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name... | [
{
"design_group_description": "Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy (patients with or without BRCA mutati... | [
"Ovarian Cancer",
"Fallopian Tube Cancer",
"Primary Peritoneal Carcinoma"
] | [
"Shanghai Gynecologic Oncology Group"
] | [
"Fudan University"
] | [
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": "ベバシズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00818961 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000630617"
]
},
{
"id_domain": "Northside Hospital, Inc",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"BMTGG-NSH-756"
]
}
] | https://clinicaltrials.gov/study/NCT00818961 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-vers... | Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies | [
{
"description": "43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)",
"name": "alemtuzumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Campath"
],
"type": "Biological"
},
{
"description": "curative potential of a... | [
{
"design_group_description": "All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type",
"design_group_title": "Hematopoietic Stem Cell Transplantation",
"design_group_type": "Other",
"intervention": [
{
"intervention_descrip... | [
"Leukemia",
"Lymphoma",
"Myelodysplastic Syndromes",
"Myelodysplastic/Myeloproliferative Diseases"
] | [
"Northside Hospital, Inc."
] | [
"Blood & Marrow Transplant Group of Georgia PC"
] | [
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT00123656 | [
{
"id_field": "org_study_id",
"id_value": [
"12790"
]
}
] | https://clinicaltrials.gov/study/NCT00123656 | Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis | Eosinophilic esophagitis (EE) is a recently recognized entity. It has been thought to be related to both allergies and acid reflux. There have been reports that both swallowed, aerosolized steroids and proton pump inhibitors have been effective treatments. The researchers propose to directly compare the efficacy of aer... | Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis | [
{
"description": "esomeprazole dosed qam for 8 weeks",
"name": "esomeprazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Nexium"
],
"type": "Drug"
},
{
"description": "fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks",
"name": "fluti... | [
{
"design_group_description": "fluticasone",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "fluticasone dosed 220 mcg 2 puffs swallowed BID ... | [
"Esophagitis"
] | [
"University of Utah"
] | [
"American Society for Gastrointestinal Endoscopy"
] | [
[
{
"name": "埃索美拉唑镁",
"lang": "CN"
},
{
"name": "Esomeprazole Magnesium",
"lang": "EN"
},
{
"name": "エソメプラゾールマグネシウム水和物",
"lang": "JP"
}
],
[
{
"name": "丙酸氟替卡松",
"lang": "CN"
},
{
"name": "Fluticasone Propionate",
"la... | null |
NCT06462235 | [
{
"id_field": "org_study_id",
"id_value": [
"C3601010"
]
},
{
"id_domain": "CTIS (EU)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"2023-507757-15-01"
]
},
{
"id_field": "acronym",
"id_value": [
"CHERISH"
]
}
] | https://clinicaltrials.gov/study/NCT06462235 | A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) | The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria.<br/>The study medicine is a combination of an antibiotic, aztreonam (ATM), and another medicine, avibactam (AVI), which is used to help stop ... | A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM ± METRONIDAZOLE IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 9 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGE... | [
{
"description": "Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.",
"name": "Part A: ATM-AVI Single Dose, Cohorts 1-4",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Multiple intr... | [
{
"design_group_description": "Single dose pharmacokinetics.",
"design_group_title": "Part A, Cohorts 1-4",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Single intravenou... | [
"Gram-negative Bacterial Infection"
] | [
"Pfizer Inc."
] | [
"AbbVie, Inc."
] | [
[
{
"name": "阿维巴坦钠/氨曲南",
"lang": "CN"
},
{
"name": "Avibactam Sodium/Aztreonam",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CHERISH"
}
] |
NCT02409368 | [
{
"id_field": "org_study_id",
"id_value": [
"CA209-171"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-001285-10"
]
},
{
"id_field": "acronym",
"id_value": [
"Checkmate 171"
]
}
] | https://clinicaltrials.gov/study/NCT02409368 | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or after at least 1 systemic therapy. | An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC | [
{
"name": "Nivolumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Nivolumab IV infusion",
"design_group_title": "Cohort A: Treatment - Nivolumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Nivolumab",
... | [
"Non-Small Cell Lung Cancer"
] | [
"Bristol Myers Squibb Co."
] | [
"Pharmaceutical Product Development LLC"
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5094d2489593d3e8aa9e3de8a984da24",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "e843e5045d82deda82242e42250aee95",
"s... |
NCT05765500 | [
{
"id_field": "org_study_id",
"id_value": [
"22-599"
]
}
] | https://clinicaltrials.gov/study/NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in thei... | RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer | [
{
"description": "Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.",
"name": "Relugolix",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Orgovyx"
],
"type": "Drug"
},
{
"description": "Gonadotropin-releasing hormone (GnRH) a... | [
{
"design_group_description": "55 participants will be randomized in a 1:1 fashion to Relugolix and stratified by intent to treat with radiation and will complete study procedures as outlined:<br/>* Surveys at baseline and at months 3, 6, 9, and 12.<br/>* Medication diary entries.<br/>* Cycles 1 - 6:<br/> --Da... | [
"Prostate Cancer",
"Prostatic Neoplasms"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"Pfizer Inc.",
"Prostate Cancer Foundation of Australia",
"Sumitomo Pharma Switzerland GmbH"
] | [
[
{
"name": "瑞卢戈利",
"lang": "CN"
},
{
"name": "Relugolix",
"lang": "EN"
},
{
"name": "レルゴリクス",
"lang": "JP"
}
]
] | null |
NCT06043674 | [
{
"id_field": "org_study_id",
"id_value": [
"23-429"
]
},
{
"id_field": "secondary_id",
"id_value": [
"23-429"
]
}
] | https://clinicaltrials.gov/study/NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT).<br/>The names of the study drugs involved in this research study ... | A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | [
{
"description": "\"2:1\" T-cell bispecific humanized monoclonal antibody, administered via intravenous infusion per protocol.",
"name": "Glofitamab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"RO7082859"
],
"type": "Drug"
},
{
"description": "Human... | [
{
"design_group_description": "Study procedures will be conducted as follows:<br/>* Baseline visit with screening procedures, including bone marrow biopsy and Positron Emission Tomography (PET) or Computed Topography (CT) scans.<br/>* PET/CT scans after 4, 8, and 12 cycles of therapy and at 6 and 15 months afte... | [
"Chronic Lymphocytic Leukemia",
"Richter's Transformation"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"Loxo Oncology, Inc.",
"Genentech, Inc.",
"Eli Lilly & Co."
] | [
[
{
"name": "维泊妥珠单抗",
"lang": "CN"
},
{
"name": "Polatuzumab Vedotin-Piiq",
"lang": "EN"
},
{
"name": "ポラツズマブ ベドチン（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "托珠单抗",
"lang": "CN"
},
{
"name": "Tocilizumab",
"lang": "EN"... | null |
NCT01930110 | [
{
"id_field": "org_study_id",
"id_value": [
"CLASS-06"
]
}
] | https://clinicaltrials.gov/study/NCT01930110 | Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes | Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion o... | An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes | [
{
"description": "Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.",
"name": "60-minute exercise",
"normalized_type": "ffd65a2d86... | [
{
"design_group_description": "In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels",
"design_group_title": "Single-hormone closed-loop system",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981... | [
"Type 1 Diabetes"
] | [
"Institut de recherches cliniques de Montréal"
] | [
"Société Francophone Du Diabete"
] | [
[
{
"name": "Glucagon(Xeris Pharmaceuticals, Inc.)",
"lang": "EN"
}
]
] | null |
NCT05401786 | [
{
"id_field": "org_study_id",
"id_value": [
"M21RAD"
]
},
{
"id_field": "acronym",
"id_value": [
"RAD-IO"
]
},
{
"id_field": "secondary_id",
"id_value": [
"M21RAD"
]
},
{
"id_field": "bridge_id",
"id_value": [
"CTIS2022-500713-79-00"
... | https://clinicaltrials.gov/study/NCT05401786 | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | Still many advanced non-small cell lung cancer (NSCLC) patients do not benefit from PD-(L)1 inhibition or will eventually develop progression through secondary resistance. Inhibition of CTLA-4, application of radiotherapy together with PD-1 inhibition showed synergistic effects and is deemed safe. | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC | [
{
"description": "Anti-CTLA-4",
"name": "Ipilimumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "PD-1 inhibition",
"name": "Cemiplimab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description... | [
{
"design_group_description": "Participants will receive 1 dose of ipilimumab (1mg/kg intravenously) on day 1. After 1 week the participants will receive SBRT (3x8Gy) on at least 1 but no more than 4 tumor lesions.<br/>Within 1 week of the last radiation fraction participants will start with cemiplimab (350mg i... | [
"Carcinoma, Non-Small-Cell Lung"
] | [
"Netherlands Cancer Insitute"
] | [
"Genzyme Corp."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "塞普利单抗",
"lang": "CN"
},
{
"name": "Cemiplimab-RWLC",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "805a923258e02e98834e5888d4a545e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "RAD-IO"
}
] |
NCT03614221 | [
{
"id_field": "org_study_id",
"id_value": [
"MOST107-2320-B-182A-002 -MY3"
]
}
] | https://clinicaltrials.gov/study/NCT03614221 | Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis | The aims of this study are:<br/>1. Compare the efficacy of Lindioil ointment and Protopic® ointment in treating atopic dermatitis.<br/>2. Compare the safety of Lindioil ointment and Protopic® ointment in treating atopic dermatitis.<br/>3. Compare the time to relapse after ceasing of treatment of Lindioil ointment and P... | Comparison of the Efficacy and Safety of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® (Tacrolimus 0.1%) Ointment in Treating Atopic Dermatitis: A Randomized, Evaluator-blind, Crossover, Active-Controlled Trial | [
{
"description": "Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.",
"name": "Lindioil ointment",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Indigo naturalis oil extract ointment"
]... | [
{
"design_group_description": "Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA... | [
"Atopic Dermatitis"
] | [
"Chang Gung Memorial Hospital"
] | [
"Ministry of Science and Technology"
] | [
[
{
"name": "他克莫司",
"lang": "CN"
},
{
"name": "Tacrolimus",
"lang": "EN"
},
{
"name": "タクロリムス水和物",
"lang": "JP"
}
]
] | null |
NCT00901524 | [
{
"id_field": "org_study_id",
"id_value": [
"ANRS HC20 ETOC"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2008-000859-10"
]
},
{
"id_field": "acronym",
"id_value": [
"ETOC"
]
}
] | https://clinicaltrials.gov/study/NCT00901524 | ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV | The purpose of this study is to assess the effectiveness of an optimized anti HCV treatment (360μg per week of PegIFN-alpha2a + 18mg/kg/j of Ribavirin for 6 months. | ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360μg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in... | [
{
"description": "Pilot study, multicenter, open label",
"name": "Peg-interféron alpha 2a + ribavirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "PegIFN- alpha 2a + RBV",
"design_group_type": "No Intervention",
"intervention": [
{
"intervention_description": "Pilot study, multicenter, open label",
"intervention_name": "Peg-interféron alpha 2a + ribavirin",
"intervention_type": "Drug",
... | [
"Hepatitis"
] | [
"France Recherche Nord & Sud SIDA HIV-Hepatites"
] | [
"Roche Pharma AG"
] | [
[
{
"name": "Peginterferon alfa-2a(Rhein-Minapharm)",
"lang": "EN"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
{
"name": "リバビリン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ETOC"
}
] |
NCT03233230 | [
{
"id_field": "org_study_id",
"id_value": [
"MS200527-0060"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2017-000384-32"
]
}
] | https://clinicaltrials.gov/study/NCT03233230 | Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis | The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development. | A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate | [
{
"description": "Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.",
"name": "M2591 25 mg QD",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Evobrutinib"
],
"type": "Drug"
},
{
"description": "Participants received... | [
{
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Participants received placebo matched to M2951 orally for 12 weeks.",
"intervent... | [
"Rheumatoid Arthritis"
] | [
"EMD Serono Research & Development Institute, Inc."
] | [
"Merck KGaA"
] | [
[
{
"name": "埃沃布鲁替尼",
"lang": "CN"
},
{
"name": "Evobrutinib",
"lang": "EN"
}
]
] | null |
NCT00357396 | [
{
"id_field": "org_study_id",
"id_value": [
"05-059"
]
},
{
"id_field": "secondary_id",
"id_value": [
"MSKCC-05059"
]
}
] | https://clinicaltrials.gov/study/NCT00357396 | Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors | RATIONALE: Giving chemotherapy drugs, such as busulfan, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of tumor cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marr... | A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatment of High Risk Ewing's Sarcoma Family Tumors | [
{
"name": "graft versus host disease prophylaxis/therapy",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "busulfan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "melphalan",
"normalized_type": "... | [
{
"design_group_description": "* Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.<br/>* Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bo... | [
"Sarcoma"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン",
"lang": "JP"
}
],
[
{
"name": "美法仑",
"lang": "CN"
},
{
"name": "Melphalan",
"lang": "EN"
},
{
"name": "メルファラン... | null |
NCT05635045 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAU0561"
]
}
] | https://clinicaltrials.gov/study/NCT05635045 | Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR | This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan.<br/>Ten previously scanned subjects re-consented to u... | A Follow-Up Study to Monitor Therapeutic Response in Transthyretin Cardiac Amyloidosis Using Amyloid Reactive Peptide 124I-evuzamitide (AT01) PET/CT | [
{
"description": "Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging",
"name": "I 124-Evuzamitide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Attralus AT-01"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Subjects treated with tafamidis selected to re-scan to determine the change over time in Evuzamitide uptake",
"design_group_title": "Stabilizer Only",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"... | [
"Transthyretin Amyloidosis"
] | [
"Columbia University"
] | [
"Attralus, Inc."
] | [
[
{
"name": "Iodine (124I) evuzamitide",
"lang": "EN"
}
]
] | null |
NCT00418535 | [
{
"id_field": "org_study_id",
"id_value": [
"2004-10-08"
]
}
] | https://clinicaltrials.gov/study/NCT00418535 | Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma | Nasal NK/T-cell lymphoma is a peculiar clinico-pathologic subtype of non-Hodgkin's lymphoma (NHL). Although most patients present with stage I/II, only 30-60% of the patients remain disease-free. The efficacy of the conventional anthracycline-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone [C... | A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma | [
{
"name": "Concurrent Radiotherapy (RT)/cisplatin, VIPD",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Lymphoma, T-Cell"
] | [
"Samsung Medical Center"
] | [
"Korea University Anam Hospital",
"Gyeongsang National University Hospital",
"Asan Medical Center"
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
]
] | null |
NCT02647944 | [
{
"id_field": "org_study_id",
"id_value": [
"15-001783"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R56DK067071"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UL1TR... | https://clinicaltrials.gov/study/NCT02647944 | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use. | Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity | [
{
"description": "Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (<br/>4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately eve... | [
{
"design_group_description": "Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approxima... | [
"Obesity"
] | [
"Mayo Clinic"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"Novo Nordisk A/S"
] | [
[
{
"name": "利拉鲁肽",
"lang": "CN"
},
{
"name": "Liraglutide",
"lang": "EN"
},
{
"name": "リラグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT07426822 | [
{
"id_field": "org_study_id",
"id_value": [
"2000037614"
]
},
{
"id_field": "acronym",
"id_value": [
"SAFE-CAP"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2000037614"
]
}
] | https://clinicaltrials.gov/study/NCT07426822 | Rash & Diarrhea Prophylaxis With Capivasertib | This is a randomized, multicenter, phase II clinical trial evaluating prophylactic strategies to mitigate common toxicities associated with capivasertib in combination with fulvestrant in participants with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who are eligible for this treatment regimen. | A Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer | [
{
"description": "400 mg orally, twice daily (BID), on 4-days-on/3-days-off schedule.",
"name": "Capivasertib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2 mg orally once daily on capivasertib dosing days",
"name": "Loperamide",
"norma... | [
{
"design_group_description": "All participants will receive capivasertib + fulvestrant. Capivasertib will be administered at 400 mg orally, twice daily (BID), on 4-days-on/3-days-off schedule. Fulvestrant will be administered at 500 mg intramuscularly (IM) every 14 days for the first three injections, and ever... | [
"Metastatic HR+/HER2- Breast Cancer"
] | [
"Yale University"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "盐酸西替利嗪",
"lang": "CN"
},
{
"name": "Cetirizine Hydrochloride",
"lang": "EN"
},
{
"name": "セチリジン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "氟维司群",
"lang": "CN"
},
{
"name": "Fulvestrant",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SAFE-CAP"
}
] |
NCT02344225 | [
{
"id_field": "org_study_id",
"id_value": [
"349622"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1U54HD071594"
]
},
{
"id_field": "acronym",
"id_value": [
"SPIPROP"
]
}
] | https://clinicaltrials.gov/study/NCT02344225 | Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study) | Phase 2, open-label, randomized, multi-center studies in infants and premature infants are necessary to determine treatment and preventative strategies for ROP. This study was designed to: a) target infants at the highest risk of ROP in a large number of centers with variable rates of ROP (all stages and severe ROP or ... | Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP STUDY) | [
{
"description": "Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)",
"name": "Caffeine citrate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Caffeine"
],
"type": "Drug"
},
{
"description": "Ibuprofen (10 mg/kg loading dose fo... | [
{
"design_group_description": "Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention",
"design_group_title": "Caffeine... | [
"Retinopathy of Prematurity"
] | [
"State University of New York at Downstate Medical Center"
] | [
"US Food & Drug Administration",
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "酮咯酸氨丁三醇",
"lang": "CN"
},
{
"name": "Ketorolac Tromethamine",
"lang": "EN"
}
],
[
{
"name": "布洛芬",
"lang": "CN"
},
{
"name": "Ibuprofen",
"lang": "EN"
},
{
"name": "イブプロフェン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "e252e2eea4232084080224838d22aa22",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SPIPROP"
}
] |
NCT00334256 | [
{
"id_field": "org_study_id",
"id_value": [
"ANRS 12109 TEmAA"
]
},
{
"id_field": "acronym",
"id_value": [
"TEmAA"
]
}
] | https://clinicaltrials.gov/study/NCT00334256 | Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA) | To study the pharmacokinetic properties, safety and viral resistance pattern of the combination of tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their newborns, with a view to prevention of mother-to-child transmission (PMTCT) of HIV-1 in Africa and Asia. | Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia | [
{
"name": "Tenofovir (TDF)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Emtricitabine (FTC)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"HIV Infection",
"Pregnancy"
] | [
"France Recherche Nord & Sud SIDA HIV-Hepatites"
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "替诺福韦",
"lang": "CN"
},
{
"name": "Tenofovir",
"lang": "EN"
}
],
[
{
"name": "恩曲他滨",
"lang": "CN"
},
{
"name": "Emtricitabine",
"lang": "EN"
},
{
"name": "エムトリシタビン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TEmAA"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ANRS 12109 TEmAA"
}
] |
NCT03926195 | [
{
"id_field": "org_study_id",
"id_value": [
"GLPG0634-CL-227"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-003933-14"
]
},
{
"id_field": "acronym",
"id_value": [
"MANTA-RAy"
]
}
] | https://clinicaltrials.gov/study/NCT03926195 | Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis | The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.<br/>Results of this study may be pooled with the results of a separate study being co... | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis | [
{
"description": "200-mg tablet administered orally once daily",
"name": "Filgotinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"GS-6034",
"Jyseleca®"
],
"type": "Drug"
},
{
"description": "Placebo to match filgotinib tablet administered oral... | [
{
"design_group_description": "Participants received filgotinib 200 milligrams (mg) tablet, orally, once daily up to Week 13 in the double-blind (DB) phase. At Week 13, participants who were arthritis responders, were unblinded and received open-label (OL) treatment filgotinib 200 mg, tablet, orally, once daily... | [
"Rheumatoid Arthritis",
"Psoriatic Arthritis",
"Ankylosing Spondylitis",
"Non-Radiographical Axial Spondyloarthritis"
] | [
"Galapagos NV"
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "非戈替尼",
"lang": "CN"
},
{
"name": "Filgotinib Maleate",
"lang": "EN"
},
{
"name": "フィルゴチニブマレイン酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MANTA-RAy"
}
] |
NCT05969496 | [
{
"id_field": "org_study_id",
"id_value": [
"22-1669.cc"
]
},
{
"id_field": "acronym",
"id_value": [
"NEOPAX"
]
}
] | https://clinicaltrials.gov/study/NCT05969496 | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus | The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient rela... | Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX) | [
{
"description": "Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.",
"name": "Axitinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Inlyta"
],
"type": "Drug"
},
{
"description": "Pemb... | [
{
"design_group_description": "Neoadjuvant therapy with the combination of Pembrolizumab and Axitinib will be given for eligible RCC patients with an IVC TT for a total of 12 weeks. Patients will then undergo imaging with a contrast enhanced, diffusion weighted imaging MRI of the abdomen to evaluate the IVC TT ... | [
"Renal Cancer",
"Kidney Cancer",
"Renal Cell Carcinoma",
"Inferior Vena Cava Thrombosis"
] | [
"University of Colorado Denver"
] | [
"Cancer League of Colorado"
] | [
[
{
"name": "阿昔替尼",
"lang": "CN"
},
{
"name": "Axitinib",
"lang": "EN"
},
{
"name": "アキシチニブ",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name":... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NEOPAX"
}
] |
NCT04186988 | [
{
"id_field": "org_study_id",
"id_value": [
"1471901"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2019-07768"
]
},
{
"id_domain": "University of California Davi... | https://clinicaltrials.gov/study/NCT04186988 | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy | This trial studies how well [18F]-AraG works in detecting T-cell activation in patients with non-small cell lung cancer that has spread to other places in the body (advanced), who are undergoing PD-1/PD-L1-directed therapy. [18F]-AraG is a "radiotracer" which attaches to immune cells directed at the cancer and shines a... | Imaging of T-Cell Activation With [18F]-AraG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1-Directed Therapy | [
{
"description": "Given IV",
"name": "Fluorine F 18 Ara-G",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"18F-F-Ara-G",
"[18F]F-AraG",
"[18F]F-ara-G"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients receive [18F]-AraG IV and then undergo PET/CT over 2 hours at baseline and within 2 weeks after starting immunotherapy. Patients may also undergo blood sample collection.",
"design_group_title": "Diagnostic ([18F]-AraG)",
"design_group_type": "Experimental",
"... | [
"Advanced Lung Non-Small Cell Carcinoma",
"Metastatic Lung Non-Small Cell Carcinoma",
"Stage III Lung Cancer AJCC v8",
"Stage IIIA Lung Cancer AJCC v8",
"Stage IIIB Lung Cancer AJCC v8",
"Stage IIIC Lung Cancer AJCC v8",
"Stage IV Lung Cancer AJCC v8",
"Stage IVA Lung Cancer AJCC v8",
"Stage IVB Lun... | [
"University of California, Davis"
] | [
"National Cancer Institute",
"CellSight Technologies, Inc."
] | [
[
{
"name": "[18F]F-AraG",
"lang": "EN"
}
]
] | null |
NCT05098171 | [
{
"id_field": "org_study_id",
"id_value": [
"GC201-2021-10hospital-Gyne"
]
}
] | https://clinicaltrials.gov/study/NCT05098171 | A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital) | This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surroundin... | A Clinical Study on Signal Switch Receptor Modified Tumor Infiltrating Lymphocytes Injection (GC201 TIL) in Patients With Gynecologic Tumors | [
{
"description": "Adoptive transfer of 2x10^8-1x10^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.",
"name": "Signal Switch Receptor Modified TIL",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "2x10^8-1x10^10 in vitro expanded autologous PD-1 or TGF-β signal switch receptor modified TIL (GC201 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.",
"d... | [
"Advanced Gynecologic Tumors",
"Signal Switch Receptor Modified TIL",
"Treatment Side Effects",
"Effects of Immunotherapy"
] | [
"Shanghai Gencells Therapeutics Co., Ltd."
] | [
"Shanghai No. 10 People's Hospital"
] | [
[
{
"name": "GC201 TIL(Shanghai Gencells Therapeutics)",
"lang": "EN"
}
]
] | null |
NCT06653556 | [
{
"id_field": "org_study_id",
"id_value": [
"LB2305-0001"
]
}
] | https://clinicaltrials.gov/study/NCT06653556 | A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus | This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory systemic lupus erythematosus. | An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCAR-AIO for the Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) | [
{
"description": "Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.",
"name": "LCAR-AIO T cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Experimental: Chimeric antigen receptor T cells (LCAR-AIO)<br/>Each subject will be given a single-dose LCAR-AIO cells infusion at each dose level",
"design_group_title": "LCAR-AIO T Cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5... | [
"Systemic Lupus Erythematosus (SLE)"
] | [
"Wuhan Xiehe Hospital Tower"
] | [
"Nanjing Legend Biotech Co., Ltd."
] | [
[
{
"name": "LCAR-AIO(Legend Biotech)",
"lang": "EN"
}
]
] | null |
NCT06414408 | [
{
"id_field": "org_study_id",
"id_value": [
"AI186641"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AI186641"
]
},
{
"id_field": "acronym",
"id_value": [
"DOT-Doxy-PEP"
]
}
] | https://clinicaltrials.gov/study/NCT06414408 | Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP | Rates of bacterial sexually transmitted infections (STIs) are rising globally, demanding innovative interventions beyond the scope of current efforts to prevent STIs. The United States Doxycycline Post-exposure Prophylaxis (DoxyPEP) Study has demonstrated the efficacy of doxycycline post-exposure prophylaxis (PEP) amon... | Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP | [
{
"description": "200mg Dose",
"name": "Doxycycline Pill",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants will be randomized to take once daily doxycycline 200mg for six weeks.",
"design_group_title": "Daily Dosing",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Sexually Transmitted Diseases, Bacterial"
] | [
"The University of California, San Francisco"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "盐酸多西环素",
"lang": "CN"
},
{
"name": "Doxycycline Hyclate",
"lang": "EN"
},
{
"name": "ドキシサイクリン塩酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DOT-Doxy-PEP"
}
] |
NCT03001349 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-0030"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-01894"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03001349 | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find a... | An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC | [
{
"description": "Undergo PET/CT",
"name": "Computed Tomography",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"CAT",
"CAT Scan",
"CT",
"CT SCAN",
"Computerized Axial Tomography",
"computerized tomography",
"tomography"
],
"... | [
{
"design_group_description": "Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.",
"design_group_title": "Diagnostic (gallium Ga 68-edotreotide, PET/CT)",
"design_group_type": "Experimental",
"design_group_type_normalized_id... | [
"Meningioma",
"Metastatic Well Differentiated Neuroendocrine Neoplasm",
"Multiple Endocrine Neoplasia Type 1",
"Neuroendocrine Neoplasm",
"Somatostatin Positive Neoplastic Cells Present",
"Von Hippel-Lindau Syndrome"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "镓[68Ga]伊索曲肽",
"lang": "CN"
},
{
"name": "68Ga-Edotreotide",
"lang": "EN"
}
]
] | null |
NCT02042196 | [
{
"id_field": "org_study_id",
"id_value": [
"06-0537 SHAPE2"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R56HL114073-06A1"
]
},
{
"id_field": "acronym",
"id_value": [
"SHAPE2"
]
}
] | https://clinicaltrials.gov/study/NCT02042196 | Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women | As women get older and go through menopause, levels of the female reproductive hormone estradiol decrease to low levels. Also with aging, the functioning of the arteries declines. Over time this vascular dysfunction can lead to health problems such as high blood pressure and heart disease. This study is being done to h... | Biological Mechanisms of Vascular Dysfunction With Age and Estrogen Deficiency | [
{
"description": "KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.",
"name": "KUVAN",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tetrahydrobiopterin or BH4"
],
"type": "Drug"
... | [
{
"design_group_description": "Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN<br/>Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVA... | [
"Menopause",
"Aging"
] | [
"University of Colorado Denver"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "醋酸西曲瑞克",
"lang": "CN"
},
{
"name": "Cetrorelix",
"lang": "EN"
},
{
"name": "セトロレリクス酢酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸沙丙蝶呤",
"lang": "CN"
},
{
"name": "Sapropterin Dihydrochloride",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SHAPE2"
}
] |
NCT06092047 | [
{
"id_field": "org_study_id",
"id_value": [
"PG-CART-UTAA09-001"
]
}
] | https://clinicaltrials.gov/study/NCT06092047 | UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. | This study is designed for exploring the preliminary safety and efficacy of the recombinant allogeneic healthy γδT cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell hematolymphatic malignancies. | Clinical Study of Universal Off-the-shelf Cell Products in Patients With CD19-positive Relapsed/Refractory B-cell Hematolymphatic Malignancies. | [
{
"description": "Intravenous injection, dosage:1-10×10^8 CAR+ γδT cells, Cell concentration: 2×10^7 cells/mL.",
"name": "UTAA09 cells for infusion",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "30 mg/m^2/day×4 days",
"name": "Fludarabi... | [
{
"design_group_description": "Off-the-shelf γδT cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day-7<br/>Day-2.",
"design_group_title": "U... | [
"CD19-positive Relapsed or Refractory B-cell Malignancies"
] | [
"PersonGen BioTherapeutics (Suzhou) Co., Ltd."
] | [
"Anhui Provincial Hospital"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | null |
NCT04853082 | [
{
"id_field": "org_study_id",
"id_value": [
"DL-MAFLD-TCM"
]
},
{
"id_domain": "Clinical Research Plan of SHDC",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"SHDC2020CR4095"
]
},
{
"id_field": "acronym",
"id_value": [... | https://clinicaltrials.gov/study/NCT04853082 | Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution | The prevention and treatment of metabolic-related fatty liver disease (MAFLD) involves many fields in preventive medicine and clinical medicine. So far, western medicine has not yet completed the elucidation of the mechanism of this type of disease, and there is a lack of effective therapeutic drugs.The purpose of this... | Clinical Trial of Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution | [
{
"description": "All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with h... | [
{
"design_group_description": "Limonene capsules(marketed product in China) donate by pharmaceutical company",
"design_group_title": "Limonene capsules(marketed product in China)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"i... | [
"Fatty Liver"
] | [
"Shanghai Jiao Tong University School of Medicine"
] | [
"Shanghai Shen Kang Hospital Development Center",
"Shanghai Jiao Tong University",
"Longhua Hospital Shanghai University of TCM"
] | [
[
{
"name": "柠檬烯",
"lang": "CN"
},
{
"name": "Limonene",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DL-MAFLD-TCM"
}
] |
NCT02113657 | [
{
"id_field": "org_study_id",
"id_value": [
"2013-0444"
]
},
{
"id_domain": "NCI CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2014-01205"
]
},
{
"id_domain": "Stand Up to Cancer",
"id_field": "secondary_id",
"... | https://clinicaltrials.gov/study/NCT02113657 | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | The goal of this clinical research study is to study the impact of ipilimumab on the immune system of patients currently receiving hormone therapy. The safety of these drug combinations will also be studied.<br/>This is an investigational study. Ipilimumab is FDA approved and commercially available for the treatment of... | A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma | [
{
"description": "3 mg/kg by vein once every 3 weeks for a total of 4 doses.",
"name": "Ipilimumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BMS-734016",
"MDX010",
"Yervoy"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.",
"design_group_title": "Ipilimumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Prostate Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Bristol Myers Squibb Co.",
"Stand Up To Cancer"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT07213882 | [
{
"id_field": "org_study_id",
"id_value": [
"APHP240605"
]
},
{
"id_field": "acronym",
"id_value": [
"CITY"
]
}
] | https://clinicaltrials.gov/study/NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) | Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphomas characterized by a primary involvement of the skin. Among them, mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes. SS is defined as erythroderma (erythema of the entire skin surface), and circulating tumor blood cells. T... | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) | [
{
"description": "This study use the Bayesian one-stage time-to-event continual reassessment method (TITE-CRM) design for dose finding phase I clinical trials, using an empirical dose-toxicity model with linear weights. A maximum total of 30 patients with CTCL, given 4 candidate dose levels (0.3; 1.0; 3.0; 10.0... | [
{
"design_group_title": "single agent DT-7012",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "This study use the Bayesian one-stage time-to-event continual reassessment method... | [
"Cutaneous T Cell Lymphoma (CTCL)",
"Mycosis Fungoides",
"Sezary Syndrome"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"Kainova Therapeutics, Inc."
] | [
[
{
"name": "DT-7012",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CITY"
}
] |
NCT01640301 | [
{
"id_field": "org_study_id",
"id_value": [
"2498.00"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-03362"
]
},
{
"id_field": "secondary_id",
"id_value":... | https://clinicaltrials.gov/study/NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia (CML) that has returned after a period of improvement (relapsed), previously treate... | Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML | [
{
"description": "Given SC",
"name": "Aldesleukin",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"125-L-Serine-2-133-interleukin 2",
"Proleukin",
"Recombinant Human IL-2",
"Recombinant Human Interleukin-2",
"r-serHuIL-2"
],
"type": "Bio... | [
{
"design_group_description": "Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.",
"design_group_title": "Arm I (high-risk for relapse after HCT)",
"desi... | [
"Recurrent Adult Acute Myeloid Leukemia",
"Recurrent Childhood Acute Myeloid Leukemia",
"Secondary Acute Myeloid Leukemia",
"Therapy-Related Acute Myeloid Leukemia",
"Donor",
"Hematopoietic Cell Transplant Recipient",
"HLA-A*0201 Positive Cells Present",
"Recurrent Acute Myeloid Leukemia"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "WT1-Sensitized Allogeneic T-Lymphocytes(NCI)",
"lang": "EN"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"n... | null |
NCT02886559 | [
{
"id_field": "org_study_id",
"id_value": [
"CN301-XYK-003"
]
}
] | https://clinicaltrials.gov/study/NCT02886559 | Chidamide Plus DCAG for Relapsed/Refractory AML | Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge.The investigators designed a new regimen, including chidamide, decitabine, aclarubincin, cytarabine and G-CSF, to treat rrAML. | null | [
{
"description": "chidamide, decitabine, aclarubicin, cytarabine and G-CSF",
"name": "Chidamide plus DCAG regimen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"DCCAG regimen"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Chidamide 30mg twice for one week decitabine 20mg/m^2 for 5 days",
"design_group_title": "DCCAG",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description... | [
"AML",
"Relapse"
] | [
"Chinese People's Liberation Army General Hospital"
] | [
"Navy General Hospital"
] | [
[
{
"name": "地西他滨",
"lang": "CN"
},
{
"name": "Decitabine",
"lang": "EN"
}
],
[
{
"name": "西达本胺",
"lang": "CN"
},
{
"name": "Chidamide",
"lang": "EN"
},
{
"name": "ツシジノスタット",
"lang": "JP"
}
],
[
{
"... | null |
NCT03400254 | [
{
"id_field": "org_study_id",
"id_value": [
"UPCC 10117"
]
},
{
"id_field": "acronym",
"id_value": [
"GLACIER"
]
}
] | https://clinicaltrials.gov/study/NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | This clinical trial will assess the safety and early efficacy of the role of gedatolisib and hydroxychloroquine in early-stage breast cancer patients with residual disease and evidence of disseminated tumor cells (DTCs) on bone marrow aspirate after neoadjuvant chemotherapy (NACT) and definitive surgery. | A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | [
{
"description": "All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day... | [
{
"design_group_description": "Patients will receive HCQ, 600 mg BID, for 24 weeks.",
"design_group_title": "Phase II: Arm A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description":... | [
"Breast Cancer"
] | [
"Abramson Cancer Center"
] | [
"Pfizer Inc.",
"The Breast Cancer Research Foundation",
"Hoosier Cancer Research Network"
] | [
[
{
"name": "硫酸羟氯喹",
"lang": "CN"
},
{
"name": "Hydroxychloroquine Sulfate",
"lang": "EN"
},
{
"name": "ドロキシクロロキン硫酸塩",
"lang": "JP"
}
],
[
{
"name": "吉达利塞",
"lang": "CN"
},
{
"name": "Gedatolisib",
"lang": "EN"
}... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GLACIER"
}
] |
NCT03294083 | [
{
"id_field": "org_study_id",
"id_value": [
"JX594-REN026"
]
}
] | https://clinicaltrials.gov/study/NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with Cemipli... | A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) | [
{
"description": "Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells",
"name": "Pexastimogene Devacirepvec (Pexa-Vec)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
... | [
{
"design_group_description": "Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.<br/>Cemiplimab wil... | [
"Renal Cell Carcinoma"
] | [
"SillaJen, Inc."
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
[
{
"name": "塞普利单抗",
"lang": "CN"
},
{
"name": "Cemiplimab-RWLC",
"lang": "EN"
},
{
"name": "セミプリマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Pexastimogene devacirepvec",
"lang": "EN"
}
]
] | null |
NCT02180711 | [
{
"id_field": "org_study_id",
"id_value": [
"ACE-LY-003"
]
},
{
"id_domain": "CTIS (EU)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"2023-509350-63-00"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"i... | https://clinicaltrials.gov/study/NCT02180711 | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.<br/>Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR.<br/>Part 3: To characterize the safety of acalabrutin... | An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | [
{
"name": "acalabrutinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ACP-196"
],
"type": "Drug"
},
{
"name": "rituximab (IV)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Lenalidomide",
"norma... | [
{
"design_group_description": "acalabrutinib Regimen 1 for relapsed, refractory Follicular Lymphoma subjects",
"design_group_title": "Part 1: acalabrutinib Regimen 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Non Hodgkin Lymphoma"
] | [
"Acerta Pharma BV"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "阿可替尼",
"lang": "CN"
},
{
"name": "Acalabrutinib",
"lang": "EN"
},
{
"n... | null |
NCT00538616 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00002077"
]
},
{
"id_field": "acronym",
"id_value": [
"PrePARE"
]
}
] | https://clinicaltrials.gov/study/NCT00538616 | Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion | The purpose of this study is to evaluate brain injury when two different drugs (propofol and precedex) are used to sedate patients who need a neurologic exam. | A Phase IV Single Center Cross Over Clinical Study Comparing Two Different Sedations Strategies for Mechanically Ventilated Patients With Neurological Critical Illness | [
{
"description": "in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)",
"name": "Dexmedetomidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Precedex"
],
"type": "Drug"
},
{
"description... | [
{
"design_group_description": "Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.",
"design_group_title": "Precedex-Propofol",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a... | [
"Brain Injury",
"Intracranial Pressure"
] | [
"Duke University"
] | [
"Hospira, Inc."
] | [
[
{
"name": "盐酸右美托咪定",
"lang": "CN"
},
{
"name": "Dexmedetomidine Hydrochloride",
"lang": "EN"
},
{
"name": "デクスメデトミジン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "丙泊酚",
"lang": "CN"
},
{
"name": "Propofol",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a82ea22892ea2a582085a222235050a5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PrePARE"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.